Herbicide resistant plants
The introduction of anti-ALS, PPO, ACCase and HPPD mutants in wheat and rice plants through base editing technology has solved the problem of herbicide damage to crops in the prior art, achieved resistance to herbicides, and improved weeds Controlled efficiency and crop growth and yield.
Patent Information
- Application Number
- CN202411411002.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-09-27
- Filing Date
- 2020-09-11
- Publication Date
- 2024-12-06
AI Technical Summary
The development of inhibitory herbicides for para-acetyllactate synthase (ALS), protoporphyrinogen oxidase (PPO), acetyl-CoA carboxylase (ACCase) and para-hydroxyphenylpyruvate bioxidase (HPPD) is difficult to develop Resistant crop plants that cause herbicides to cause harm to the crop when controlling weeds.
Mutants that are resistant to ALS, PPO, ACCase and HPPD inhibitory herbicides were created and identified by base editing techniques, and these mutants were introduced into wheat and rice plants to confer resistance to the plants to herbicides.
It realizes effective weed control without damaging the crop when using herbicides, improves the herbicide resistance of the crop, and reduces the damage to the growth and yield of the crop.
Smart Images

Figure BDA0005077981090000231 
Figure BDA0005077981090000241 
Figure BDA0005077981090000251
Abstract
Description
[0001] This application is a divisional application of the invention patent application with an application date of September 11, 2020, application number 202080063995.X, and invention name “Herbicide-resistant plants”. Technical Field
[0002] The present invention relates to the field of plant genetic engineering. Specifically, the present invention relates to acetolactate synthase (ALS) mutants, protoporphyrinogen oxidase (PPO) mutants, acetyl-CoA carboxylase (ACCase) mutants and / or p-hydroxyphenylpyruvate dioxygenase (HPPD) mutants capable of conferring herbicide resistance in plants, especially wheat and / or rice plants, and methods for producing herbicide-resistant plants, especially wheat and / or rice plants, comprising said acetolactate synthase (ALS) mutants and / or protoporphyrinogen oxidase (PPO) mutants and / or acetyl-CoA carboxylase (ACCase) mutants and / or p-hydroxyphenylpyruvate dioxygenase (HPPD) mutants. Background of the Invention
[0004] A major threat to crop production such as wheat and rice is weed competition, which results in reduced grain yields and poor quality. Although weeds can be eliminated by tillage, the soil of tilled land is susceptible to erosion by wind and water. Herbicide treatments are the preferred method of weed control due to ease of application and effectiveness. Herbicides can also provide weed control in direct seeding systems that reduce tillage or are designed to leave high levels of residue on the soil surface to prevent erosion.
[0005] The development of herbicide resistance in plants provides important production and economic advantages; therefore, the use of herbicides to control weeds or undesirable plants in crops has become almost universal practice. However, the use of such herbicides can also cause the death or reduction of growth of the desired crop plants, which makes the timing and method of herbicide application quite critical or in some cases simply unfeasible. To address this problem, one approach has been to develop herbicide-resistant varieties. In this approach, herbicides are applied to crops to control weeds without causing damage to the herbicide-resistant crop.
[0006] Of particular interest to farmers is the use of herbicides with greater potency, broad weed spectrum effectiveness and rapid soil degradation. Plants, plant tissues and seeds resistant to these compounds offer an attractive solution by allowing the use of herbicides to control weed growth without the risk of crop damage.
[0007] Broad-spectrum herbicides include those compounds that inhibit acetolactate synthase (ALS) activity, protoporphyrinogen oxidase (PPO) activity, acetyl-CoA carboxylase (ACCase) activity, or para-hydroxyphenylpyruvate dioxidase (HPPD) activity in plants. However, wheat is susceptible to many ALS- or PPO-inhibiting herbicides targeting monocots, while rice is susceptible to many ACCase-inhibiting herbicides or HPPD-inhibiting herbicides targeting monocots, making it almost impossible to use these herbicides to control grass weeds.
[0008] Therefore, there is still a need in the art to develop crop plants, such as wheat and / or rice, that are resistant to ALS and / or PPO and / or ACCase and / or HPPD inhibiting herbicides. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 An alignment of the amino acid sequences of ALS encoded by wheat A, B and D genomes is shown. This alignment can be used to determine, for example, the amino acid position numbers of the ALS amino acid sequence encoded by the reference A genome.
[0011] Figure 2 The amino acid sequence alignment of PPO encoded by wheat A, B and D genomes is shown. This alignment can be used to determine the amino acid position number, for example, with reference to the amino acid sequence of PPO encoded by the A genome.
[0012] Figure 3 The figure shows the rice resistance mutants that survived after the spraying of high-efficiency fluazifop-butyl. The resistance mutants that survived in the upper figure are S1866F heterozygous mutant, A1884P heterozygous mutant, and P2128L homozygous mutant; the resistance mutants that survived in the lower figure are P1927F homozygous and heterozygous mutants. The heart leaves of the wild-type Zhonghua No. 11 (WT) in the upper and lower figures all dried up and died. The coordinate ruler is 1 cm long.
[0013] Figure 4 The mutation types of the resistant mutants generated by targeting the four sites OsACC-S1866, OsACC-A1884, OsACC-P2181, and OsACC-P1927 are shown. Summary of the invention
[0014] I. Definition
[0015] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, immunology related terms and laboratory operation procedures used herein are terms and routine procedures widely used in the corresponding fields. For example, the standard recombinant DNA and molecular cloning techniques used in the present invention are well known to those skilled in the art and are more fully described in the following documents: Sambrook, J., Fritsch, EF and Maniatis, T., Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter referred to as "Sambrook"). At the same time, in order to better understand the present invention, the definitions and explanations of the relevant terms are provided below.
[0016] As used herein, the term "and / or" encompasses all combinations of items connected by the term, and each combination should be considered to have been listed separately herein. For example, "A and / or B" encompasses "A," "A and B," and "B." For example, "A, B, and / or C" encompasses "A," "B," "C," "A and B," "A and C," "B and C," and "A and B and C."
[0017] When the term "comprising" is used herein to describe a protein or nucleic acid sequence, the protein or nucleic acid may consist of the sequence, or may have additional amino acids or nucleotides at one or both ends of the protein or nucleic acid, but still have the activity described in the present invention. In addition, it is clear to those skilled in the art that the methionine encoded by the start codon at the N-terminus of the polypeptide may be retained in certain practical situations (for example, when expressed in a specific expression system), but it does not substantially affect the function of the polypeptide. Therefore, when describing a specific polypeptide amino acid sequence in the specification and claims of this application, although it may not contain a methionine encoded by a start codon at the N-terminus, a sequence containing the methionine is also covered at this time, and accordingly, its encoding nucleotide sequence may also contain a start codon; and vice versa.
[0018] "Exogenous" with respect to a sequence refers to a sequence that is from a foreign species, or, if from the same species, a sequence that has been significantly altered in composition and / or locus from its native form through deliberate human intervention.
[0019] "Polynucleotide," "nucleic acid sequence," "nucleotide sequence," or "nucleic acid" are used interchangeably and are single-stranded or double-stranded RNA or DNA polymers that optionally may contain synthetic, non-natural, or altered nucleotide bases. Nucleotides are referred to by their single-letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" is cytidine or deoxycytidine, "G" is guanosine or deoxyguanosine, "U" is uridine, "T" is deoxythymidine, "R" is a purine (A or G), "Y" is a pyrimidine (C or T), "K" is G or T, "H" is A or C or T, "D" is A, T or G, "I" is inosine, and "N" is any nucleotide.
[0020] Codon optimization refers to a method of modifying a nucleic acid sequence to enhance expression in a host cell of interest by replacing at least one codon of the native sequence (e.g., about or more than about 1, 2, 3, 4, 5, 10, 15, 20, 25, 50 or more codons) with codons that are more frequently or most frequently used in the genes of the host cell while maintaining the native amino acid sequence. Different species exhibit specific preferences for certain codons for specific amino acids. Codon bias (differences in codon usage between organisms) is often correlated with the efficiency of translation of messenger RNA (mRNA), which in turn is believed to depend on the nature of the codons being translated and the availability of specific transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell generally reflects the codons that are most frequently used for peptide synthesis. Therefore, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, in the Codon Usage Database available at www.kazusa.orjp / codon / , and these tables can be adapted for use in different ways. See, Nakamura et al., 2001. Y. et al., "Codon usage tabulated from the international DNA sequence databases: status for the year 2000. Nucl. Acids Res., 28:292 (2000).
[0021] "Polypeptide", "peptide", and "protein" are used interchangeably herein to refer to polymers of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, as well as to naturally occurring amino acid polymers. The terms "polypeptide", "peptide", "amino acid sequence" and "protein" may also include modified forms, including but not limited to glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
[0022] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the full length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Although there are many methods to measure the identity between two polynucleotides or polypeptides, the term "identity" is well known to those of skill (Carrillo, H. & Lipman, D., SIAM J Applied Math 48: 1073 (1988)).
[0023] In peptides or proteins, suitable conservative amino acid substitutions are known to those skilled in the art, and generally can be carried out without changing the biological activity of the resulting molecule. Generally, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially change biological activity (see, e.g., Watson et al., Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub.co., p. 224).
[0024] As used herein, "expression construct" refers to a vector such as a recombinant vector suitable for expressing a nucleotide sequence of interest in an organism. "Expression" refers to the production of a functional product. For example, the expression of a nucleotide sequence can refer to the transcription of the nucleotide sequence (such as transcription to generate mRNA or functional RNA) and / or the translation of RNA into a precursor or mature protein.
[0025] The "expression construct" of the present invention can be a linear nucleic acid fragment, a circular plasmid, a viral vector, or, in some embodiments, can be a translatable RNA (such as mRNA), for example, RNA generated by in vitro transcription.
[0026] An "expression construct" of the present invention may comprise regulatory sequences and a nucleotide sequence of interest from different sources, or regulatory sequences and a nucleotide sequence of interest from the same source but arranged in a manner different from that normally found in nature.
[0027] "Regulatory sequence" and "regulatory element" are used interchangeably and refer to nucleotide sequences located upstream (5' non-coding sequence), in the middle or downstream (3' non-coding sequence) of a coding sequence and affecting the transcription, RNA processing or stability or translation of the relevant coding sequence. Regulatory sequences may include, but are not limited to, promoters, translation leader sequences, introns and polyadenylation recognition sequences.
[0028] "Promoter" refers to a nucleic acid fragment that can control the transcription of another nucleic acid fragment. In some embodiments of the present invention, a promoter is a promoter that can control the transcription of a gene in a cell, whether or not it is derived from the cell. A promoter can be a constitutive promoter or a tissue-specific promoter or a developmentally regulated promoter or an inducible promoter.
[0029] "Constitutive promoter" refers to a promoter that will generally cause a gene to be expressed in most cell types under most circumstances. "Tissue-specific promoter" and "tissue-preferred promoter" are used interchangeably and refer to a promoter that is expressed primarily, but not necessarily exclusively, in one tissue or organ, and may also be expressed in one specific cell or cell type. "Developmentally regulated promoter" refers to a promoter whose activity is determined by developmental events. "Inducible promoter" selectively expresses an operably linked DNA sequence in response to endogenous or exogenous stimuli (environmental, hormonal, chemical signals, etc.).
[0030] Examples of promoters include, but are not limited to, polymerase (pol) I, pol II or pol III promoters. When used in plants, the promoter can be cauliflower mosaic virus 35S promoter, corn Ubi-1 promoter, wheat U6 promoter, rice U3 promoter, corn U3 promoter, rice actin promoter.
[0031] As used herein, the term "operably linked" refers to the connection of a regulatory element (e.g., but not limited to, a promoter sequence, a transcription termination sequence, etc.) to a nucleic acid sequence (e.g., a coding sequence or an open reading frame) such that transcription of the nucleotide sequence is controlled and regulated by the transcription regulatory element. Techniques for operably linking a regulatory element region to a nucleic acid molecule are known in the art.
[0032] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming an organism cell with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation. "Stable transformation" refers to the introduction of an exogenous nucleotide sequence into a genome, resulting in stable inheritance of the exogenous gene. Once stably transformed, the exogenous nucleic acid sequence is stably integrated into the genome of the organism and any successive generations thereof. "Transient transformation" refers to the introduction of a nucleic acid molecule or protein into a cell, performing a function without stable inheritance of the exogenous gene. In transient transformation, the exogenous nucleic acid sequence is not integrated into the genome.
[0033] As used herein, the term "plant" includes the whole plant and any offspring, cells, tissues, or parts of the plant. The term "plant part" includes any part of a plant, including, for example, but not limited to: seeds (including mature seeds, immature embryos without seed coats, and immature seeds); plant cuttings; plant cells; plant cell cultures; plant organs (e.g., pollen, embryos, flowers, fruits, buds, leaves, roots, stems, and related explants). Plant tissues or plant organs can be seeds, callus, or any other plant cell population organized into structural or functional units. Plant cells or tissue cultures can regenerate plants with the physiological and morphological characteristics of the plant from which the cells or tissues are derived, and can regenerate plants with substantially the same genotype as the plant. In contrast, some plant cells are not able to regenerate plants. The regenerable cells in plant cell or tissue culture can be embryos, protoplasts, meristems, callus, pollen, leaves, anthers, roots, root tips, silk, flowers, kernels, ears, cobs, husks, or stems.
[0034] Plant "progeny" include any subsequent generations of the plant.
[0035] Acetolactate synthase mutants conferring herbicide resistance
[0036] Acetolactate synthase (ALS) is a key enzyme in the synthesis of branched-chain amino acids in plants, microorganisms and fungi. Branched-chain amino acids include valine, leucine and isoleucine, which are essential amino acids for protein synthesis and plant growth in plants. The biosynthesis pathway of branched-chain amino acids requires the participation of four enzymes. Among them, acetolactate synthase is responsible for catalyzing the production of acetolactate and carbon dioxide from two molecules of pyruvate in the first step of the synthesis of valine and leucine, and is responsible for catalyzing the production of 2-acetaldehyde-2-hydroxybutyrate and carbon dioxide from one molecule of pyruvate and one molecule of α-butyric acid in the synthesis of isoleucine. If the activity of ALS is inhibited or destroyed, it will lead to the deficiency of the three essential amino acids, thereby affecting the normal growth of plants.
[0037] ALS-inhibiting herbicides include, but are not limited to, sulfonylureas (SU), imidazolinones (IMI), triazolopyrimidines (TP), pyrimidinylthiobenzoic acid (PTB) and sulfonylamino-carbonyl-triazolinone (SCT) compounds, or any combination thereof. Suitable sulfonylurea compounds include, but are not limited to, chlorimuron-methyl, primisulfuron-methyl, bensulfuron-methyl, metsulfuron-methyl, chlorsulfuron-methyl, bensulfuron-methyl, metsulfuron-methyl, thifensulfuron-methyl, pyrazosulfuron-methyl, amidosulfuron-methyl, nicosulfuron-methyl, and the like. Examples of suitable imidazolinone compounds include, but are not limited to, imazethapyr, imazapic, imazaquin, and the like. Other suitable ALS inhibitors include, but are not limited to, penoxsulam, fluazifop-butyl, bispyribac-sodium, and the like.
[0038] In the present invention, the inventors created and identified new ALS mutants resistant to ALS-inhibiting herbicides through base editing technology.
[0039] Therefore, in one aspect, the present invention provides an acetolactate synthase (ALS) mutant or a functional fragment thereof, which has an amino acid mutation at one or more positions selected from positions 99, 98, 101 and 102 relative to wild-type ALS, and the ALS amino acid position refers to SEQ ID NO:1.
[0040] As used herein, "amino acid position reference SEQ ID NO: x" (SEQ ID NO: x is a specific sequence listed herein) means that the position number of the specific amino acid described is the position number of the amino acid corresponding to the amino acid in SEQ ID NO: x. The correspondence of amino acids in different sequences can be determined according to sequence alignment methods known in the art. For example, amino acid correspondence can be determined using the online alignment tool of EMBL-EBI ( https: / / www.ebi.ac.uk / Tools / psa / ), where the two sequences can be aligned using the Needleman-Wunsch algorithm using default parameters. For example, if the alanine at position 98 from the N-terminus in the wild-type ALS encoded by the wheat B genome is aligned with the amino acid at position 99 of SEQ ID NO:1 (wild-type ALS encoded by the wheat A genome) in the sequence alignment, then the alanine can be described herein as "the alanine at position 99 of the wild-type ALS encoded by the wheat B genome, the ALS amino acid position being referenced to SEQ ID NO:1".
[0041] In some embodiments, the ALS mutant or a functional fragment thereof, when expressed in a plant, can confer resistance to a herbicide on the plant.
[0042] In some embodiments, the ALS mutant is derived from a wheat wild-type ALS. In some embodiments, the wheat wild-type ALS is a wild-type ALS encoded by the wheat A genome. An exemplary wild-type ALS encoded by the wheat A genome comprises the amino acid sequence set forth in SEQ ID NO:1. In some embodiments, the wheat wild-type ALS is a wild-type ALS encoded by the wheat B genome. An exemplary wild-type ALS encoded by the wheat B genome comprises the amino acid sequence set forth in SEQ ID NO:2. In some embodiments, the wheat wild-type ALS is a wild-type ALS encoded by the wheat D genome. An exemplary wild-type ALS encoded by the wheat D genome comprises the amino acid sequence set forth in SEQ ID NO:3.
[0043] In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with alanine (A) at position 99, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with glycine (G) at position 98, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with methionine (M) at position 101, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with glutamic acid (E) at position 102, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with alanine (A) at position 99 and with glycine (G) at position 98, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with alanine (A) at position 99, and the ALS amino acid positions are referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof is substituted with alanine (A) at position 99, substituted with glycine (G) at position 98, substituted with methionine (M) at position 101, and substituted with glutamic acid (E) at position 102, and the ALS amino acid positions are referenced to SEQ ID NO: 1.
[0044] In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has alanine (A) substituted by threonine (T) at position 99, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has a glycine (G) substituted by asparagine (N) at position 98, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has a methionine (M) substituted by isoleucine (I) at position 101, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has a glutamic acid (E) substituted by lysine (K) at position 102, and the ALS amino acid position is referenced to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has alanine (A) at position 99 replaced by threonine (T), and glycine (G) at position 98 replaced by asparagine (N), and the ALS amino acid positions refer to SEQ ID NO: 1. In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof has alanine (A) at position 99 replaced by threonine (T), glycine (G) at position 98 replaced by asparagine (N), methionine (M) at position 101 replaced by isoleucine (I), and glutamic acid (E) at position 102 replaced by lysine (K), and the ALS amino acid positions refer to SEQ ID NO: 1.
[0045] In some embodiments, relative to wild-type ALS, the ALS mutant or a functional fragment thereof comprises one or more amino acid substitutions selected from A99T, G98N, M101I, E102K, and the ALS amino acid positions refer to SEQ ID NO:1.
[0046] As used herein, a "functional fragment" of an ALS mutant refers to a fragment that at least partially or fully retains the function of the full-length ALS mutant from which it is derived.
[0047] In some embodiments, the ALS mutant or a functional fragment thereof further comprises one or more additional amino acid mutations, such as conservative amino acid substitutions, relative to wild-type ALS.
[0048] In some embodiments, the ALS mutant or a functional fragment thereof comprises an amino acid sequence having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or even 100% sequence identity with any one of SEQ ID NOs:4-8.
[0049] 3. Protoporphyrinogen oxidase mutants conferring herbicide resistance
[0050] Protoporphyrinogen oxidase (PPO) catalyzes the reaction of protoporphyrinogen IX to form protoporphyrin IX in chlorophyll synthesis and is a key enzyme in the chlorophyll synthesis process. PPO is located in the chloroplast. When the enzyme is inhibited, it will cause the light-sensitive protoporphyrinogen IX to accumulate rapidly and penetrate through the chloroplast membrane into the cytoplasm outside the chloroplast. In the cytoplasm, protoporphyrinogen IX is automatically oxidized to protoporphyrin IX. High concentrations of protoporphyrin IX will produce toxic singlet oxygen under the action of light and oxygen, thereby causing peroxidation of unsaturated fatty acids in the cell membrane, leading to membrane leakage, pigment destruction, and ultimately leaf death.
[0051] PPO-inhibiting herbicides include, but are not limited to, diphenyl ethers, cyclic imines, phenylpyrazoles, bicyclic triazolones, or any combination thereof. Suitable PPO-inhibiting herbicides include, but are not limited to, acifluorfen, pyraclostrobin, cyfluthrin, fluazifop-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, flufenacet-butyl, lactofen, oxadiazine, oxadiazine, oxyfluorfen, pyraclostrobin, saflufenacil, sulfentrazone, and foramsulfuron.
[0052] In the present invention, the inventors created and identified new PPO mutants resistant to PPO-inhibiting herbicides through base editing technology.
[0053] Therefore, in one aspect, the present invention provides a protoporphyrinogen oxidase (PPO) mutant or a functional fragment thereof, which has an amino acid mutation at one or more positions selected from positions 127 and 129 relative to wild-type PPO, and the PPO amino acid positions refer to SEQ ID NO:9.
[0054] In some embodiments, the PPO mutant or a functional fragment thereof, when expressed in a plant, can confer resistance to a herbicide on the plant.
[0055] In some embodiments, the PPO mutant is derived from a wheat wild-type PPO. In some embodiments, the wheat wild-type PPO is a wild-type PPO encoded by the wheat A genome. An exemplary wild-type PPO encoded by the wheat A genome comprises the amino acid sequence shown in SEQ ID NO:9. In some embodiments, the wheat wild-type PPO is a wild-type PPO encoded by the wheat B genome. An exemplary wild-type PPO encoded by the wheat B genome comprises the amino acid sequence shown in SEQ ID NO:10. In some embodiments, the wheat wild-type PPO is a wild-type PPO encoded by the wheat D genome. An exemplary wild-type PPO encoded by the wheat D genome comprises the amino acid sequence shown in SEQ ID NO:11.
[0056] In some embodiments, relative to the wild-type PPO, the PPO mutant or a functional fragment thereof is substituted with arginine (R) at position 127, and the amino acid positions of the PPO are referred to SEQ ID NO: 9. In some embodiments, relative to the wild-type PPO, the PPO mutant or a functional fragment thereof is substituted with threonine (T) at position 129, and the amino acid positions of the PPO are referred to SEQ ID NO: 9. In some embodiments, relative to the wild-type PPO, the PPO mutant or a functional fragment thereof is substituted with arginine (R) at position 127 and threonine (T) at position 129, and the amino acid positions of the PPO are referred to SEQ ID NO: 9.
[0057] In some embodiments, relative to the wild-type PPO, the arginine (R) at position 127 of the PPO mutant or a functional fragment thereof is replaced by cysteine (C) or glycine (G), and the amino acid positions of the PPO are referred to as SEQ ID NO: 9. In some embodiments, relative to the wild-type PPO, the threonine (T) at position 129 of the PPO mutant or a functional fragment thereof is replaced by isoleucine (I), and the amino acid positions of the PPO are referred to as SEQ ID NO: 9. In some embodiments, relative to the wild-type PPO, the arginine (R) at position 127 of the PPO mutant or a functional fragment thereof is replaced by cysteine (C) or glycine (G), and the threonine (T) at position 129 is replaced by isoleucine (I), and the amino acid positions of the PPO are referred to as SEQ ID NO: 9.
[0058] In some embodiments, relative to wild-type PPO, the PPO mutant or a functional fragment thereof comprises one or more amino acid substitutions selected from R127C, R127G, T129I, and the amino acid positions of the PPO refer to SEQ ID NO:9.
[0059] As used herein, a "functional fragment" of a PPO mutant refers to a fragment that at least partially or fully retains the function of the full-length PPO mutant from which it is derived.
[0060] In some embodiments, the PPO mutant or a functional fragment thereof further comprises one or more additional amino acid mutations, such as conservative amino acid substitutions, relative to wild-type PPO.
[0061] In some embodiments, the PPO mutant or a functional fragment thereof comprises an amino acid sequence having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5%, or even 100% sequence identity to any one of SEQ ID NOs: 12-16.
[0062] ACCase mutants conferring herbicide resistance
[0063] Acetyl-CoA carboxylase (ACCase) is a biotinylating enzyme that catalyzes the carboxylation of acetyl-CoA to generate malonyl-CoA. This carboxylation is a two-step reversible reaction consisting of ATP-dependent carboxylation of the biotin group of the carboxyl carrier domain by biotin carboxylase activity, followed by transfer of the carboxyl group from biotin to acetyl-CoA by carboxyltransferase activity (Nikolau et al., 2003, Arch. Biochem. Biophys. 414: 211-22). Acetyl-CoA carboxylase is not only a key enzyme for fatty acid synthesis in plants (the synthesis process occurs in chloroplasts and mitochondria), but ACCase also plays a role in the formation of long-chain fatty acids and flavonoids, as well as in the malonylation process that occurs in the cytoplasm. There are two isoforms of ACCase, of which the chloroplast ACCase accounts for more than 80% of the total ACCase activity (Herbert et al., 1996, Biochem. J. 318: 997-1006). Aryloxyphenoxypropionates (FOP) and cyclohexanediones (DIM) are two classes of chemicals known to selectively inhibit chloroplast ACCase in weeds (Rendina et al., 1990, J. Agric. Food Chem. 38: 1282-1287). In addition, phenylpyrazolines (DEN) can also inhibit ACCase activity.
[0064] In the present invention, the inventors created and identified new ACCase mutants resistant to herbicides such as aryloxyphenoxypropionate (FOP), cyclohexanedione (DIM) or phenylpyrazoline (DEN) herbicides through base editing technology.
[0065] Therefore, in one aspect, the present invention provides an ACCase mutant or a functional fragment thereof, which has an amino acid mutation at one or more positions selected from 1866, 1884, 1927 or 2181 relative to wild-type ACCase, wherein the ACCase amino acid position refers to SEQ ID NO:31.
[0066] In some embodiments, the ACCase mutant or a functional fragment thereof, when expressed in a plant, can confer resistance to a herbicide on the plant.
[0067] The herbicides described in various embodiments of the present invention include herbicides capable of inhibiting ACCase activity (ACCase inhibitors), such as aryloxyphenoxypropionates, cyclohexanediones or phenylpyrazolines, or any combination thereof. Examples of suitable aryloxyphenoxypropionate herbicides include, but are not limited to, clodinafop-propargyl, cyhalofop-butyl, diclofop-methyl, fenoxaprop-p-ethyl, fluazifop-b-butyl, haloxyfop-ethoxyethyl, haloxyfop-etotyl, haloxyfop-R-methyl, propaquizafop, quizalofop-p-ethyl, haloxyfop-P, or any combination thereof. Examples of suitable cyclohexanedione herbicides include, but are not limited to, alloxydim, butroxydim, clefoxydim, clethodim, cycloxydim, profoxydim, sethoxydim, teproloxydim and tralkoxydim, or any combination thereof. Examples of suitable phenylpyrazoline herbicides include, but are not limited to, pinoxaden.
[0068] In some embodiments, the ACCase mutant is derived from a wild-type rice ACCase. An exemplary wild-type rice ACCase comprises an amino acid sequence as shown in SEQ ID NO:31.
[0069] In some embodiments, relative to the wild-type ACCase, the serine (S) at position 1866 of the ACCase mutant or its functional fragment is substituted, and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the alanine (A) at position 1884 of the ACCase mutant or its functional fragment is substituted, and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the proline (P) at position 1927 of the ACCase mutant or its functional fragment is substituted, and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the proline (P) at position 2181 of the ACCase mutant or its functional fragment is substituted, and the amino acid position of the ACCase is referenced to SEQ ID NO: 31.
[0070] In some embodiments, relative to the wild-type ACCase, the serine (S) at position 1866 of the ACCase mutant or its functional fragment is replaced by phenylalanine (F), and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the alanine (A) at position 1884 of the ACCase mutant or its functional fragment is replaced by proline (P), and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the proline (P) at position 1927 of the ACCase mutant or its functional fragment is replaced by phenylalanine (F), and the amino acid position of the ACCase is referenced to SEQ ID NO: 31. In some embodiments, relative to the wild-type ACCase, the proline (P) at position 2181 of the ACCase mutant or its functional fragment is replaced by leucine (L), and the amino acid position of the ACCase is referenced to SEQ ID NO: 31.
[0071] In some embodiments, relative to wild-type ACCase, the ACCase mutant or a functional fragment thereof comprises one or more amino acid substitutions selected from S1866F, A1884P, P1927, P2181L, and the amino acid position of the ACCase refers to SEQ ID NO:31.
[0072] As used herein, "functional fragment" refers to a fragment that retains at least partially or completely the function of the full-length ACCase mutant from which it is derived. For example, the functional fragment includes at least the carboxyl transferase (CT) domain of ACCase and contains the amino acid mutations described above. The amino acid sequence of an exemplary wild-type ACCase carboxyl transferase (CT) domain is shown in SEQ ID NO:36.
[0073] In some embodiments, relative to wild-type ACCase, the ACCase mutant or its functional fragment further comprises one or more additional amino acid mutations, such as conservative amino acid substitutions. Preferably, the additional amino acid mutations are located outside the CT domain.
[0074] In some embodiments, the ACCase mutant or a functional fragment thereof comprises an amino acid sequence as shown in any one of SEQ ID NOs: 32-35 or 37-40. In some embodiments, the ACCase mutant or a functional fragment thereof comprises an amino acid sequence having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% sequence identity with any one of SEQ ID NOs: 32-35 or 37-40.
[0075] 5. HPPD mutants conferring herbicide resistance
[0076] Para-hydroxyphenylpyruvate dioxygenase (HPPD) participates in two metabolic pathways: tyrosine catabolism and the biosynthesis of plastoquinone and tocopherol. Para-hydroxyphenylpyruvate is converted into homogentisic acid under the catalysis of HPPD enzyme. Homodisic acid is further decarboxylated and alkylated to generate plastoquinone and tocopherol. Plastoquinone serves as the final electron acceptor in carotenoid biosynthesis and the electron transporter in the photosynthetic chain. The lack of plastoquinone in thylakoids will lead to a reduction in carotenoid biosynthesis. Para-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors have a broad spectrum of herbicidal activity and can control broadleaf weeds in broadleaf crops. They can be used before germination or after germination, and have the characteristics of high activity, low residue, good environmental compatibility, and safe use.
[0077] HPPD-inhibiting herbicides include, but are not limited to, pyrazoles, triketones, isoxazoles, diketonitriles and benzophenone compounds, or any combination thereof. Suitable pyrazole compounds include, but are not limited to, benzylpyrazol (Baowei), sulfonylpyrazol, acid phenylazopyramine, etc. Suitable triketone compounds include, but are not limited to, sulfotrione, mesotrione, terbotrione, terfurfuryl ester ketone, bicyclic pyrone, benzobicyclic ketone, etc. Suitable isoxazole compounds include, but are not limited to, isoxazolidinone. Suitable diketonitrile compounds include, but are not limited to, 2-cyano-3-cyclopropyl-1-(2-methylsulfonyl-4-trifluoromethylphenyl)-propane-1,3-dione and 2-cyano-1-[4-(methylsulfonyl)-2-trifluoromethylphenyl]-3-(1-methylcyclopropyl)propane-1,3-dione.
[0078] In the present invention, the inventors created and identified new HPPD mutants resistant to HPPD-inhibiting herbicides through base editing technology.
[0079] Therefore, in one aspect, the present invention provides a HPPD mutant or a functional fragment thereof, which has an amino acid mutation at least at one or more positions selected from position 365, 379, 353, 354, 346, 347, 369 or 370 relative to the wild-type HPPD, wherein the HPPD amino acid position refers to SEQ ID NO:45.
[0080] As used herein, "amino acid position references SEQ ID NO: x" (SEQ ID NO: x is a specific sequence listed herein) means that the position number of the specific amino acid being described is the position number of the amino acid corresponding to the amino acid on SEQ ID NO: x. The correspondence of amino acids in different sequences can be determined according to sequence alignment methods known in the art. For example, amino acid correspondence can be determined by the online alignment tool of EMBL-EBI (https: / / www.ebi.ac.uk / Tools / psa / ), where two sequences can be aligned using the Needleman-Wunsch algorithm using default parameters. For example, if the amino acid at position 360 from the N-terminus of a polypeptide is aligned with the amino acid at position 365 of SEQ ID NO: x in a sequence alignment, then the amino acid in the polypeptide may also be described herein as "alanine at position 365 of the polypeptide, the amino acid position references SEQ ID NO: x".
[0081] In some embodiments, the HPPD mutant or a functional fragment thereof, when expressed in a plant, can confer resistance to a herbicide, such as an HPPD-inhibiting herbicide, on the plant.
[0082] In some embodiments, the HPPD mutant is derived from a wild-type rice HPPD. An exemplary wild-type rice HPPD comprises the amino acid sequence shown in SEQ ID NO:45.
[0083] In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with leucine (L) at position 365, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with threonine (T) at position 379, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with glutamic acid (E) at position 353, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with glutamic acid (E) at position 354, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with glutamic acid (E) at position 353 and glutamic acid (E) at position 354, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with arginine (R) at position 346, and the HPPD amino acid position is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with alanine (A) at position 347, and the HPPD amino acid position is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with arginine (R) at position 346 and alanine (A) at position 347, and the HPPD amino acid position is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with aspartic acid (D) at position 369, and the HPPD amino acid position is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with aspartic acid (D) at position 370, and the HPPD amino acid position is referenced to SEQ ID NO: 45. In some embodiments, relative to wild-type HPPD, the HPPD mutant or a functional fragment thereof is substituted with aspartic acid (D) at position 369 and aspartic acid (D) at position 370, wherein the HPPD amino acid positions refer to SEQ ID NO:45.
[0084] In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof has a leucine (L) substituted by a phenylalanine (F) at position 365, and the amino acid position of the HPPD is referred to as SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the threonine (T) at position 379 of the HPPD mutant or a functional fragment thereof is substituted by an isoleucine (I), and the amino acid position of the HPPD is referred to as SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the glutamic acid (E) at position 353 of the HPPD mutant or a functional fragment thereof is substituted by a lysine (K), and the amino acid position of the HPPD is referred to as SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the glutamic acid (E) at position 354 of the HPPD mutant or a functional fragment thereof is substituted by a lysine (K), and the amino acid position of the HPPD is referred to as SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the HPPD mutant or a functional fragment thereof has glutamic acid (E) at position 353 and glutamic acid (E) at position 354 replaced by lysine (K), respectively, and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the arginine (R) at position 346 of the HPPD mutant or a functional fragment thereof is replaced by cysteine (C), and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the alanine (A) at position 347 of the HPPD mutant or a functional fragment thereof is replaced by valine (V), and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the arginine (R) at position 346 of the HPPD mutant or a functional fragment thereof is replaced by cysteine (C) and the alanine (A) at position 347 of the HPPD mutant or a functional fragment thereof is replaced by valine (V), and the amino acid positions of the HPPD are referred to in SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the aspartic acid (D) at position 369 of the HPPD mutant or a functional fragment thereof is substituted by asparagine (N), and the amino acid position of the HPPD is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the aspartic acid (D) at position 370 of the HPPD mutant or a functional fragment thereof is substituted by asparagine (N), and the amino acid position of the HPPD is referenced to SEQ ID NO: 45. In some embodiments, relative to the wild-type HPPD, the aspartic acid (D) at position 369 and the aspartic acid (D) at position 370 of the HPPD mutant or a functional fragment thereof are substituted by asparagine (N), respectively, and the amino acid position of the HPPD is referenced to SEQ ID NO: 45.
[0085] In some embodiments, relative to wild-type HPPD, the HPPD mutant or its functional fragment comprises at least one or more amino acid substitutions selected from L365F, T379I, E353K, E354K, E353K / E354K, R346C, A347V, R346C / A347V, D369N, D370N, D369N / D370N, and the amino acid positions of the HPPD refer to SEQ ID NO: 45.
[0086] As used herein, "functional fragment" refers to a fragment that at least partially or fully retains the function of the full-length HPPD mutant from which it is derived.
[0087] In some embodiments, the HPPD mutant or a functional fragment thereof further comprises one or more additional amino acid mutations, such as conservative amino acid substitutions, relative to wild-type HPPD.
[0088] In some embodiments, the HPPD mutant comprises an amino acid sequence having at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.5% sequence identity to any one of SEQ ID NOs: 46-50. In some embodiments, the HPPD mutant comprises an amino acid sequence as shown in any one of SEQ ID NOs: 46-50.
[0089] VI. Related nucleic acids, constructs and herbicide-resistant plants
[0090] In another aspect, the present invention also provides a nucleic acid comprising a nucleotide sequence encoding an ALS mutant or a functional fragment thereof of the present invention, and / or a nucleotide sequence encoding a PPO mutant or a functional fragment thereof of the present invention, and / or a nucleotide sequence encoding an ACCase mutant or a functional fragment thereof of the present invention, and / or a nucleotide sequence encoding an HPPD mutant or a functional fragment thereof of the present invention. In some embodiments, the nucleic acid is an isolated nucleic acid or a recombinant nucleic acid.
[0091] In some embodiments, the nucleotide sequence encoding the ALS mutant of the present invention or a functional fragment thereof, and / or the nucleotide sequence encoding the PPO mutant of the present invention or a functional fragment thereof, and / or the nucleotide sequence encoding the ACCase mutant of the present invention or a functional fragment thereof, and / or the nucleotide sequence encoding the HPPD mutant of the present invention or a functional fragment thereof can be codon-optimized for the plant of interest.
[0092] On the other hand, the present invention also provides an expression cassette, which comprises a nucleotide sequence encoding an ALS mutant or a functional fragment thereof, and / or a nucleotide sequence encoding a PPO mutant or a functional fragment thereof of the present invention, and / or a nucleotide sequence encoding an ACCase mutant or a functional fragment thereof of the present invention, and / or a nucleotide sequence encoding an HPPD mutant or a functional fragment thereof of the present invention, which is operably linked to a regulatory sequence.
[0093] In another aspect, the present invention also provides an expression construct comprising the expression cassette of the present invention.
[0094] On the other hand, the present invention also provides the use of the ALS mutant or a functional fragment thereof of the present invention, the PPO mutant or a functional fragment thereof of the present invention, the ACCase mutant or a functional fragment thereof of the present invention, the HPPD mutant or a functional fragment thereof of the present invention, the isolated nucleic acid of the present invention, the expression cassette of the present invention or the expression construct of the present invention in producing herbicide-resistant plants.
[0095] On the other hand, the present invention also provides a herbicide-resistant plant, which comprises (e.g., expresses) the ALS mutant of the present invention or a functional fragment thereof, and / or the PPO mutant of the present invention or a functional fragment thereof, and / or the ACCase mutant of the present invention or a functional fragment thereof, and / or the HPPD mutant of the present invention or a functional fragment thereof.
[0096] The plants described in various aspects of the present invention may be plants that are sensitive to ALS inhibitors and / or PPO inhibitors and / or ACCase inhibitors and / or HPPD inhibitors, including monocots or dicots. Preferably, the plants are crop plants, such as monocot crop plants. Examples of suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, and the like. In some preferred embodiments, the plant is wheat. In some preferred embodiments, the plant is rice.
[0097] The herbicide resistance in various aspects of the present invention may be resistance to ALS-inhibiting herbicides and / or PPO-inhibiting herbicides and / or ACCase-inhibiting herbicides and / or HPPD-inhibiting herbicides.
[0098] VII. Methods for producing herbicide-resistant plants through genetic modification
[0099] In another aspect, the present invention also provides a method for producing herbicide-resistant plants by transgenic means, comprising introducing the nucleic acid of the present invention, the expression cassette of the present invention and / or the expression construct of the present invention into a plant.
[0100] Various methods known in the art can be used to introduce the nucleic acid of the present invention, the expression cassette of the present invention and / or the expression construct of the present invention into the plant. Suitable introduction methods include, but are not limited to, gene gun method, PEG-mediated protoplast transformation, Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube channel method and ovary injection method.
[0101] In some embodiments, the nucleic acid of the invention, the expression cassette of the invention and / or the expression construct of the invention are integrated into the genome of the plant. The isolated nucleic acid of the invention, the expression cassette of the invention and / or the expression construct of the invention will confer resistance to herbicides capable of inhibiting ALS activity and / or PPO activity and / or ACCase activity and / or HPPD activity on the plant.
[0102] In another aspect, the present invention also provides a herbicide resistant plant comprising an expression cassette of the present invention, a nucleic acid of the present invention or an expression construct, or transformed with a nucleic acid of the present invention, an expression cassette of the present invention and / or an expression construct of the present invention. The present invention also encompasses progeny of the herbicide resistant plant.
[0103] The plants described in various aspects of the present invention may be plants that are sensitive to ALS inhibitors and / or PPO inhibitors and / or ACCase inhibitors and / or HPPD inhibitors, including monocots or dicots. Preferably, the plants are crop plants, such as monocot crop plants. Examples of suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, and the like. In some preferred embodiments, the plant is wheat. In some preferred embodiments, the plant is rice.
[0104] 8. Methods for producing herbicide-resistant plants through base editing
[0105] In another aspect, the present invention also provides a method for producing a herbicide-resistant plant by base editing, comprising introducing a base editing system targeting an endogenous ALS coding region and / or an endogenous PPO coding region and / or an endogenous ACCase coding region and / or an endogenous HPPD coding region in the genome of the plant into the plant, thereby causing
[0106] (i) the endogenous ALS has an amino acid mutation at one or more positions selected from positions 99, 98, 101 and 102, wherein the ALS amino acid positions refer to SEQ ID NO: 1, and / or
[0107] (ii) the endogenous PPO has an amino acid mutation at one or more positions selected from positions 127 and 129, the PPO amino acid positions refer to SEQ ID NO: 9, and / or
[0108] (iii) the endogenous ACCase has an amino acid mutation at one or more positions selected from 1866, 1884, 1927 or 2181, wherein the amino acid position of the ACCase is referenced to SEQ ID NO: 31, and / or
[0109] (iv) the endogenous HPPD has an amino acid mutation at one or more positions selected from position 365, 379, 353, 354, 346, 347, 369 or 370, wherein the HPPD amino acid position refers to SEQ ID NO: 45.
[0110] In some embodiments, the introduction of the base editing system causes the endogenous ALS to be substituted with alanine (A) at position 99, and / or substituted with glycine (G) at position 98, and / or substituted with methionine (M) at position 101, and / or substituted with glutamate (E) at position 102, and the ALS amino acid positions refer to SEQ ID NO:1.
[0111] In some embodiments, the introduction of the base editing system results in the endogenous ALS being replaced by threonine (T) at position 99 of alanine (A), and / or substituted by asparagine (N) at position 98 of glycine (G), and / or substituted by isoleucine (I) at position 101 of methionine (M), and / or substituted by lysine (K) at position 102 of glutamic acid (E), wherein the amino acid positions of the ALS refer to SEQ ID NO:1.
[0112] In some embodiments, the introduction of the base editing system causes the endogenous ALS to contain one or more amino acid substitutions selected from A99T, G98N, M101I, E102K, and the ALS amino acid position refers to SEQ ID NO:1.
[0113] In some embodiments, the introduction of the base editing system causes the endogenous PPO to be substituted with arginine (R) at position 127 and / or substituted with threonine (T) at position 129, and the PPO amino acid positions refer to SEQ ID NO:9.
[0114] In some embodiments, the introduction of the base editing system results in the endogenous PPO being replaced by cysteine (C) or glycine (G) at position 127 of arginine (R), and / or by isoleucine (I) at position 129 of threonine (T), and the PPO amino acid positions refer to SEQ ID NO:9.
[0115] In some embodiments, the introduction of the base editing system causes the endogenous PPO to contain one or more amino acid substitutions selected from R127C, R127G, T129I, and the amino acid positions of the PPO refer to SEQ ID NO:9.
[0116] In some embodiments, the introduction of the base editing system causes the endogenous ACCase to be substituted with serine (S) at position 1866, and / or substituted with alanine (A) at position 1884, and / or substituted with proline (P) at position 1927, and / or substituted with proline (P) at position 2181, the amino acid positions of the ACCase referring to SEQ ID NO:31.
[0117] In some embodiments, the introduction of the base editing system results in the endogenous ACCase being replaced by serine (S) at position 1866 with phenylalanine (F), and / or alanine (A) at position 1884 with proline (P), and / or proline (P) at position 1927 with phenylalanine (F), and / or proline (P) at position 2181 with leucine (L), the ACCase amino acid positions referring to SEQ ID NO:31.
[0118] In some embodiments, the introduction of the base editing system causes the endogenous ACCase to contain one or more amino acid substitutions selected from S1866F, A1884P, P1927, P2181L, and the amino acid position of the ACCase refers to SEQ ID NO: 31.
[0119] In some embodiments, the introduction of the base editing system causes the endogenous HPPD to be replaced by leucine (L) at position 365, and / or threonine (T) at position 379, and / or glutamate (E) at position 353, and / or glutamate (E) at position 354, and / or arginine (R) at position 346, and / or alanine (A) at position 347, and / or aspartic acid (D) at position 369, and / or aspartic acid (D) at position 370, and the HPPD amino acid positions refer to SEQ ID NO: 45.
[0120] In some embodiments, the introduction of the base editing system causes the endogenous HPPD to be replaced by phenylalanine (F) at leucine (L) at position 365, and / or threonine (T) at position 379 is replaced by isoleucine (I), and / or glutamate (E) at position 353 is replaced by lysine (K), and / or glutamate (E) at position 354 is replaced by lysine (K), and / or arginine (R) at position 346 is replaced by cysteine (C), and / or alanine (A) at position 347 is replaced by valine (V), and / or aspartic acid (D) at position 369 is replaced by asparagine (N), and / or aspartic acid (D) at position 370 is replaced by asparagine (N), and the amino acid positions of the HPPD refer to SEQ ID NO: 45.
[0121] In some embodiments, the introduction of the base editing system causes the endogenous HPPD to contain one or more amino acid substitutions selected from L365F, T379I, E353K, E354K, E353K / E354K, R346C, A347V, R346C / A347V, D369N, D370N, D369N / D370N, and the HPPD amino acid position refers to SEQ ID NO: 45.
[0122] The base editing system available in the present invention can be various base editing systems known in the art, as long as it can perform targeted genome base editing in plants. For example, the base editing system includes but is not limited to those described in WO 2018 / 056623, WO 2019 / 120283, and WO 2019 / 120310.
[0123] In some embodiments, the base editing system comprises a base editing fusion protein or an expression construct comprising a nucleotide sequence encoding the same, and at least one guide RNA or an expression construct comprising a nucleotide sequence encoding the same, for example, the system comprises at least one of the following i) to v):
[0124] i) a base editing fusion protein, and at least one guide RNA;
[0125] ii) an expression construct comprising a nucleotide sequence encoding a base editor fusion protein, and at least one guide RNA;
[0126] iii) a base editing fusion protein, and an expression construct comprising a nucleotide sequence encoding at least one guide RNA;
[0127] iv) an expression construct comprising a nucleotide sequence encoding a base editor fusion protein, and an expression construct comprising a nucleotide sequence encoding at least one guide RNA;
[0128] v) an expression construct comprising a nucleotide sequence encoding a base editing fusion protein and a nucleotide sequence encoding at least one guide RNA;
[0129] The base editing fusion protein comprises a CRISPR effector protein and a deaminase domain, and the at least one guide RNA is capable of targeting the base editing fusion protein to an endogenous ALS coding sequence and / or an endogenous PPO coding sequence and / or an endogenous ACCase coding sequence and / or an endogenous HPPD coding sequence in the plant genome.
[0130] In the embodiments herein, "base editing fusion protein" and "base editor" are used interchangeably to refer to a protein that can mediate the replacement of one or more nucleotides in a target sequence in the genome in a sequence-specific manner.
[0131] As used herein, the term "CRISPR effector protein" generally refers to a nuclease (CRISPR nuclease) or a functional variant thereof present in a naturally occurring CRISPR system. The term encompasses any effector protein based on the CRISPR system that is capable of achieving sequence-specific targeting within a cell.
[0132] As used herein, a "functional variant" with respect to a CRISPR nuclease means that it at least retains the sequence-specific targeting ability mediated by the guide RNA. Preferably, the functional variant is a variant in which the nuclease is inactivated, i.e., it lacks double-stranded nucleic acid cleavage activity. However, CRISPR nucleases lacking double-stranded nucleic acid cleavage activity also encompass nickases, which form a nick in a double-stranded nucleic acid molecule but do not completely cut off the double-stranded nucleic acid. In some preferred embodiments of the present invention, the CRISPR effector protein of the present invention has nickase activity. In some embodiments, the functional variant recognizes a different PAM (protospacer adjacent motif) sequence relative to the wild-type nuclease.
[0133] "CRISPR effector protein" can be derived from Cas9 nuclease, including Cas9 nuclease or its functional variant. The Cas9 nuclease can be a Cas9 nuclease from different species, such as spCas9 from Streptococcus pyogenes (S.pyogenes) or SaCas9 derived from Staphylococcus aureus (S.aureus). "Cas9 nuclease" and "Cas9" are used interchangeably herein, referring to an RNA-guided nuclease including a Cas9 protein or a fragment thereof (e.g., a protein comprising an active DNA cleavage domain of Cas9 and / or a gRNA binding domain of Cas9). Cas9 is a component of the CRISPR / Cas (clustered regularly interspaced short palindromic repeats and related systems) genome editing system, which can target and cut DNA target sequences under the guidance of guide RNA to form DNA double-strand breaks (DSBs). An exemplary amino acid sequence of wild-type spCas9 is shown in SEQ ID NO: 17.
[0134] The "CRISPR effector protein" can also be derived from a Cpf1 nuclease, including a Cpf1 nuclease or a functional variant thereof. The Cpf1 nuclease can be a Cpf1 nuclease from different species, such as a Cpf1 nuclease from Francisella novicida U112, Acidaminococcus sp. BV3L6, and Lachnospiraceae bacterium ND2006.
[0135] Useful "CRISPR effector proteins" can also be derived from Cas3, Cas8a, Cas5, Cas8b, Cas8c, Cas10d, Cse1, Cse2, Csy1, Csy2, Csy3, GSU0054, Cas10, Csm2, Cmr5, Cas10, Csx11, Csx10, Csf1, Csn2, Cas4, C2c1, C2c3 or C2c2 nucleases, for example, including these nucleases or functional variants thereof.
[0136] In some embodiments, the CRISPR effector protein is a nuclease-inactivated Cas9. The DNA cleavage domain of the Cas9 nuclease is known to contain two subdomains: the HNH nuclease subdomain and the RuvC subdomain. The HNH subdomain cuts the strand complementary to the gRNA, while the RuvC subdomain cuts the non-complementary strand. Mutations in these subdomains can inactivate the nuclease activity of Cas9, forming a "nuclease-inactivated Cas9". The nuclease-inactivated Cas9 still retains the DNA binding ability guided by the gRNA.
[0137] The nuclease-inactivated Cas9 of the present invention can be derived from Cas9 of different species, for example, derived from Streptococcus pyogenes (S. pyogenes) Cas9 (SpCas9), or derived from Staphylococcus aureus (S. aureus) Cas9 (SaCas9). Mutating the HNH nuclease subdomain and the RuvC subdomain of Cas9 (for example, comprising mutations D10A and H840A) simultaneously inactivates the nuclease of Cas9 and becomes nuclease-dead Cas9 (dCas9). Mutation-inactivation of one of the subdomains can make Cas9 have nickase activity, i.e., obtain Cas9 nickase (nCas9), for example, nCas9 having only mutation D10A.
[0138] Therefore, in some embodiments of the present invention, the nuclease-inactivated Cas9 variant of the present invention comprises an amino acid substitution D10A and / or H840A relative to wild-type Cas9, wherein the amino acid numbering refers to SEQ ID NO: 17. In some preferred embodiments, the nuclease-inactivated Cas9 comprises an amino acid substitution D10A relative to wild-type Cas9, wherein the amino acid numbering refers to SEQ ID NO: 17. In some embodiments, the nuclease-inactivated Cas9 comprises the amino acid sequence shown in SEQ ID NO: 18 (nCas9 (D10A)).
[0139] When Cas9 nuclease is used for gene editing, it is usually required that the target sequence has a PAM (protospacer adjacent motif) sequence of 5'-NGG-3' at the 3' end. However, CRISPR effector proteins that recognize different PAM sequences can also be used, such as functional variants of Cas9 nucleases with different PAM sequences.
[0140] In some embodiments, the CRISPR effector protein is a Cas9 variant that recognizes the PAM sequence 5'-NG-3'. The Cas9 variant that recognizes the PAM sequence 5'-NG-3' is also referred to herein as Cas9-NG. In some embodiments, Cas9-NG comprises the following amino acid substitutions R1335V, L1111R, D1135V, G1218R, E1219F, A1322R, T1337R relative to wild-type Cas9, wherein the amino acid numbering refers to SEQ ID NO: 17. In some embodiments, the CRISPR effector protein is a nuclease-inactive Cas9 variant that recognizes the PAM sequence 5'-NG-3'. In some embodiments, the nuclease-inactivated Cas9 variant that recognizes the PAM sequence 5'-NG-3' comprises the following amino acid substitutions relative to wild-type Cas9: D10A, R1335V, L1111R, D1135V, G1218R, E1219F, A1322R, T1337R, wherein the amino acid numbering refers to SEQ ID NO: 17. In some embodiments, the nuclease-inactivated Cas9 variant that recognizes the PAM sequence 5'-NG-3' comprises the amino acid sequence shown in SEQ ID NO: 19 (nCas9-NG (D10A)).
[0141] In some embodiments, the CRISPR effector protein is a Cas9 variant that recognizes the PAM sequence 5'-NGA-3', i.e., VQR-Cas9. In some embodiments, VQR-Cas9 comprises the following amino acid substitutions relative to wild-type Cas9: D1135V, R1335Q, and T1337R, wherein the amino acid numbering is referenced to SEQ ID NO: 17. In some embodiments, the CRISPR effector protein is a nuclease-inactivated Cas9 variant that recognizes the PAM sequence 5'-NGA-3'. In some embodiments, the nuclease-inactivated Cas9 variant that recognizes the PAM sequence 5'-NGA-3' comprises the following amino acid substitutions D10A, D1135V, R1335Q, and T1337R relative to the wild-type Cas9, wherein the amino acid numbering is referenced to SEQ ID NO: 17. In some embodiments, the nuclease-inactivated Cas9 variant that recognizes the PAM sequence 5'-NG-3' comprises the amino acid sequence shown in SEQ ID NO: 20 (nCas9-VQR (D10A)).
[0142] The deaminase domain described herein may be a cytosine deamination domain or an adenine deamination domain.
[0143] As used herein, "cytosine deamination domain" refers to a domain that can accept single-stranded DNA as a substrate and catalyze the deamination of cytidine or deoxycytidine to uracil or deoxyuracil, respectively.
[0144] Examples of cytosine deaminases that can be used in the present invention include, but are not limited to, for example, APOBEC1 deaminase, activation-induced cytidine deaminase (AID), APOBEC3G, CDA1, human APOBEC3A deaminase, or functional variants thereof. In some embodiments, the cytosine deaminase is human APOBEC3A deaminase or a functional variant thereof. In some embodiments, human APOBEC3A deaminase comprises the amino acid sequence shown in SEQ ID NO: 21. In some embodiments, the cytosine deaminase is PmCDA1. In some embodiments, PmCDA1 comprises the amino acid sequence shown in SEQ ID NO: 22.
[0145] As used herein, "adenine deamination domain" refers to a domain that can accept single-stranded DNA as a substrate and catalyze adenosine or deoxyadenosine (A) to form inosine (I). In some embodiments, the adenine deaminase is a variant of Escherichia coli tRNA adenine deaminase TadA (ecTadA), for example, comprising an amino acid sequence as shown in SEQ ID NO: 23.
[0146] In some specific embodiments, the base editing fusion protein comprises an amino acid sequence as shown in SEQ ID NO:24 or 25 or 89.
[0147] As used herein, "guide RNA" and "gRNA" are used interchangeably and refer to an RNA molecule that can form a complex with a CRISPR effector protein and can target the complex to a target sequence due to a certain homology with the target sequence. The guide RNA targets the target sequence by base pairing with the complementary strand of the target sequence. For example, the gRNA used by the Cas9 nuclease or its functional variant is generally composed of crRNA and tracrRNA molecules that are partially complementary to form a complex, wherein the crRNA contains a guide sequence (also called a seed sequence) that has sufficient homology to the target sequence so as to hybridize with the complementary strand of the target sequence and guide the CRISPR complex (Cas9+crRNA+tracrRNA) to specifically bind to the target sequence sequence. However, it is known in the art that a single guide RNA (sgRNA) can be designed, which contains the features of crRNA and tracrRNA at the same time. The gRNA used by the Cpf1 nuclease or its functional variant is generally composed of only mature crRNA molecules, which may also be referred to as sgRNA. It is within the capabilities of those skilled in the art to design a suitable gRNA based on the CRISPR nuclease used and the target sequence to be edited.
[0148] In some embodiments, the at least one gRNA of the present invention comprises a target sequence in the endogenous ALS coding region, and the amino acid sequence encoded by the target sequence comprises the amino acid of the endogenous ALS at one or more positions selected from positions 99, 98, 101 and 102, and the ALS amino acid position refers to SEQ ID NO: 1. In some specific embodiments, the at least one gRNA of the present invention comprises a nucleotide sequence shown in one of SEQ ID NOs: 26-27 or a complementary sequence thereof.
[0149] In some embodiments, the at least one gRNA of the present invention comprises a target sequence in the endogenous PPO coding region, and the amino acid sequence encoded by the target sequence comprises the amino acid of the endogenous PPO at one or more positions selected from positions 127 and 129, and the PPO amino acid position is referenced to SEQ ID NO: 9. In some specific embodiments, the at least one gRNA of the present invention comprises a nucleotide sequence shown in one of SEQ ID NOs: 28-30 or a complementary sequence thereof.
[0150] In some embodiments, the gRNA of the present invention comprises a target sequence in the endogenous ACCase coding region, and the amino acid sequence encoded by the target sequence comprises the amino acid of the endogenous ACCase at one or more positions selected from 1866, 1884, 1927 or 2181, and the ACCase amino acid position refers to SEQ ID NO: 31. In some specific embodiments, the gRNA of the present invention comprises a nucleotide sequence shown in one of SEQ ID NOs: 41-44 or a complementary sequence thereof.
[0151] In some embodiments, the at least one gRNA of the present invention comprises a target sequence in the endogenous HPPD coding region, and the amino acid sequence encoded by the target sequence comprises the amino acid of the endogenous HPPD at one or more positions selected from positions 365, 379, 353, 354, 346, 347, 369 or 370, wherein the HPPD amino acid position is referenced to SEQ ID NO: 45. In some specific embodiments, the at least one gRNA of the present invention comprises a nucleotide sequence shown in one of SEQ ID NOs: 52-88 or a complementary sequence thereof.
[0152] In the method of the present invention, the base editing system can be introduced into plants by various methods known to those skilled in the art. Methods that can be used to introduce the base editing system of the present invention into plants include, but are not limited to, gene gun method, PEG-mediated protoplast transformation, Agrobacterium-mediated transformation, plant virus-mediated transformation, pollen tube channel method, and ovary injection method.
[0153] In the method of the present invention, the modification of the target sequence can be achieved by simply introducing or producing the base editing fusion protein and guide RNA in plant cells, and the modification can be stably inherited without the need to stably transform the base editing system into plants. This avoids the potential off-target effects of the stably existing base editing system and also avoids the integration of exogenous nucleotide sequences into the plant genome, thereby having higher biosafety.
[0154] In some preferred embodiments, the introduction is performed in the absence of selection pressure, thereby avoiding integration of the exogenous nucleotide sequence into the plant genome.
[0155] In some embodiments, the introduction comprises transforming the base editing system of the present invention into isolated plant cells or tissues, and then regenerating the transformed plant cells or tissues into complete plants. Preferably, the regeneration is carried out in the absence of selection pressure, that is, no selection agent for the selection gene carried on the expression vector is used during tissue culture. Not using a selection agent can improve the regeneration efficiency of the plant and obtain herbicide-resistant plants without exogenous nucleotide sequences.
[0156] In other embodiments, the base editing system of the present invention can be transformed into specific parts of the whole plant, such as leaves, stem tips, pollen tubes, panicles or hypocotyls. This is particularly suitable for the transformation of plants that are difficult to regenerate through tissue culture.
[0157] In some embodiments of the present invention, the in vitro expressed protein and / or in vitro transcribed RNA molecule is directly transformed into the plant. The protein and / or RNA molecule can achieve base editing in plant cells and then be degraded by the cells, thereby avoiding the integration of exogenous nucleotide sequences in the plant genome.
[0158] In another aspect, the present invention also provides a herbicide-resistant plant produced by the base editing method of the present invention. The present invention also encompasses the offspring of the herbicide-resistant plant.
[0159] In some embodiments of the invention, the herbicide resistant plants are non-transgenic.
[0160] The plants described in various aspects of the present invention may be plants that are sensitive to ALS inhibitors and / or PPO inhibitors and / or ACCase inhibitors and / or HPPD inhibitors, including monocots or dicots. Preferably, the plants are crop plants, such as monocot crop plants. Examples of suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, and the like. In some preferred embodiments, the plant is wheat. In some preferred embodiments, the plant is rice.
[0161] In some embodiments, the plant is wheat, and the endogenous ALS and / or endogenous PPO is encoded by the wheat A genome, B genome, and / or D genome.
[0162] IX. Methods for producing herbicide-resistant plants by physical or chemical mutagenesis
[0163] In another aspect, the present invention also provides a method for producing herbicide-resistant plants, comprising subjecting a population of the plants to physical or chemical mutagenesis and screening
[0164] (i) a plant whose endogenous ALS comprises an amino acid mutation at one or more positions selected from the group consisting of positions 99, 98, 101 and 102, wherein the ALS amino acid positions refer to SEQ ID NO: 1; and / or
[0165] (ii) a plant whose endogenous PPO comprises an amino acid mutation at one or more positions selected from positions 127 and 129, wherein the PPO amino acid positions refer to SEQ ID NO: 9; and / or
[0166] (iii) a plant in which endogenous ACCase comprises an amino acid mutation at one or more positions selected from 1866, 1884, 1927 or 2181, wherein the ACCase amino acid position is referenced to SEQ ID NO: 31; and / or
[0167] (iv) a plant whose endogenous HPPD comprises an amino acid mutation at one or more positions selected from position 365, 379, 353, 354, 346, 347, 369 or 370, wherein the HPPD amino acid positions refer to SEQ ID NO: 45.
[0168] In some embodiments, plants are screened in which endogenous ALS is substituted with alanine (A) at position 99, and / or with glycine (G) at position 98, and / or with methionine (M) at position 101, and / or with glutamate (E) at position 102, wherein the ALS amino acid positions refer to SEQ ID NO:1.
[0169] In some embodiments, plants are screened in which the alanine (A) at position 99 of the endogenous ALS is replaced by threonine (T), and / or the glycine (G) at position 98 is replaced by asparagine (N), and / or the methionine (M) at position 101 is replaced by isoleucine (I), and / or the glutamic acid (E) at position 102 is replaced by lysine (K), wherein the ALS amino acid positions refer to SEQ ID NO:1.
[0170] In some embodiments, plants are screened for endogenous ALS comprising one or more amino acid substitutions selected from A99T, G98N, M101I, E102K, wherein the ALS amino acid positions are referenced to SEQ ID NO: 1.
[0171] In some embodiments, plants are screened in which the endogenous PPO is substituted with arginine (R) at position 127 and / or substituted with threonine (T) at position 129, wherein the PPO amino acid positions refer to SEQ ID NO:9.
[0172] In some embodiments, plants are screened in which the arginine (R) at position 127 of the endogenous PPO is substituted with cysteine (C) or glycine (G), and / or the threonine (T) at position 129 is substituted with isoleucine (I), wherein the PPO amino acid positions refer to SEQ ID NO:9.
[0173] In some embodiments, plants are screened whose endogenous PPO comprises one or more amino acid substitutions selected from R127C, R127G, T129I, wherein the amino acid positions of the PPO are referenced to SEQ ID NO:9.
[0174] In some embodiments, plants in which the serine (S) at position 1866 of endogenous ACCase is substituted, and / or the alanine (A) at position 1884 is substituted, and / or the proline (P) at position 1927 is substituted, and / or the proline (P) at position 2181 is substituted are screened, wherein the amino acid positions of the ACCase are referenced to SEQ ID NO: 31.
[0175] In some embodiments, plants are screened in which the serine (S) at position 1866 of endogenous ACCase is replaced by phenylalanine (F), and / or the alanine (A) at position 1884 is replaced by proline (P), and / or the proline (P) at position 1927 is replaced by phenylalanine (F), and / or the proline (P) at position 2181 is replaced by leucine (L), wherein the amino acid positions of the ACCase are referenced to SEQ ID NO:31.
[0176] In some embodiments, plants whose endogenous ACCase comprises one or more amino acid substitutions selected from S1866F, A1884P, P1927, P2181L are screened, wherein the amino acid positions of the ACCase are referenced to SEQ ID NO:31.
[0177] In some embodiments, plants are screened in which the endogenous HPPD is substituted with leucine (L) at position 365, and / or substituted with threonine (T) at position 379, and / or substituted with glutamate (E) at position 353, and / or substituted with glutamate (E) at position 354, and / or substituted with arginine (R) at position 346, and / or substituted with alanine (A) at position 347, and / or substituted with aspartic acid (D) at position 369, and / or substituted with aspartic acid (D) at position 370, wherein the HPPD amino acid positions refer to SEQ ID NO: 45.
[0178] In some embodiments, plants are screened in which the endogenous HPPD has leucine (L) replaced by phenylalanine (F) at position 365, and / or threonine (T) replaced by isoleucine (I) at position 379, and / or glutamate (E) replaced by lysine (K) at position 353, and / or glutamate (E) replaced by lysine (K) at position 354, and / or arginine (R) replaced by cysteine (C) at position 346, and / or alanine (A) replaced by valine (V) at position 347, and / or aspartic acid (D) replaced by asparagine (N) at position 369, and / or aspartic acid (D) replaced by asparagine (N) at position 370, wherein the HPPD amino acid positions are referenced to SEQ ID NO: 45.
[0179] In some embodiments, plants are screened whose endogenous HPPD comprises one or more amino acid substitutions selected from the group consisting of L365F, T379I, E353K, E354K, E353K / E354K, R346C, A347V, R346C / A347V, D369N, D370N, D369N / D370N, wherein the HPPD amino acid positions are referenced to SEQ ID NO: 45.
[0180] In some embodiments, the physical mutagenesis can be achieved by irradiating the plant population with radioactivity. In some implementation methods, the chemical mutagenesis can be achieved by treating the plant population (eg, treating plant seeds) with ethyl methanesulfonate (EMS).
[0181] In some embodiments, the screening can be achieved by sequencing the coding sequence of the endogenous ALS and / or endogenous PPO and / or endogenous ACCase and / or endogenous HPPD.
[0182] In another aspect, the present invention also provides a herbicide-resistant plant produced by the physical or chemical mutagenesis method of the present invention. The present invention also encompasses the progeny of the herbicide-resistant plant.
[0183] The plants described in various aspects of the present invention may be plants that are sensitive to ALS inhibitors and / or PPO inhibitors and / or ACCase inhibitors and / or HPPD inhibitors, including monocots or dicots. Preferably, the plants are crop plants, such as monocot crop plants. Examples of suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, and the like. In some preferred embodiments, the plant is wheat. In some preferred embodiments, the plant is rice.
[0184] 10. Plant breeding methods
[0185] In another aspect, the present invention provides a plant breeding method, comprising crossing a first plant having herbicide resistance obtained by the above method of the present invention with a second plant not having the herbicide resistance, thereby introducing the herbicide resistance into the second plant.
[0186] The plants described in various aspects of the present invention may be plants that are sensitive to ALS inhibitors and / or PPO inhibitors and / or ACCase inhibitors and / or HPPD inhibitors, including monocots or dicots. Preferably, the plants are crop plants, such as monocot crop plants. Examples of suitable plants include, but are not limited to, rice, wheat, barley, sorghum, corn, and the like. In some preferred embodiments, the plant is wheat. In some preferred embodiments, the plant is rice. Example
[0187] Example 1. Generation and identification of wheat ALS-resistant mutants
[0188] 1. Single-base editing tools used
[0189] The PmCDA1-VQR-PBE single-base editing system fused with PmCDA1 cytosine deaminase was used. The sequence of PmCDA1 cytosine deaminase is from Nishida, K., et al. (2016). Targeted nucleobase editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 353, aaf8729. VQR-Cas9 is a variant of SpCas9 that can recognize NGA-type PAM sequences. PmCDA1 cytosine deaminase, VQR-Cas9 (D10A) and UGI parts were codon-optimized for cereal plants and commercially synthesized (GENEWIZ, Suzhou, China). Various structures were assembled into the pJIT163 backbone by the Gibson assembly method (Mut Express MultiS Fast Mutagenesis Kit, Vazyme, Nanjing, China). PCR in this work was performed using TransStart FastPfuDNA polymerase (TransGen Biotech).
[0190] 2. Construction of multi-target sgRNA and crRNA expression vectors
[0191] Design and synthesize primers with homologous sequences to the target site:
[0192] T1(W16-B)-F:GGGACGCGCCGCCAGGGTAGGGTTTTAGAGCTAGAAATAGC
[0193] T1(W16-B)-BSF: ATATTGGTCTCTCTTGGGACGCGCCGCCAGGGTAGGGTT
[0194] T2(W1)-R: CATCATGCGGCGGGGGACCTGCGCTTCTTGGTGCCGCGCC
[0195] T2(W1)-F:GCAGGTCCCCCGCCGCATGATGTTTTAGAGCTAGAAATAGC
[0196] T3(W16-D)-R: CCCTACCCCGGCGGCGCCTCCCGCCACGGATCATCTGCACAAC
[0197] T3(W16-D)-BSR:TTATAGGTCTCTAAACCCTACCCCGGCGGCGCCTCCCGC
[0198] According to the method of Xing, HL et al. A CRISPR / Cas9 toolkit for multiplex genome editing in plants. BMC Plant Biol. 14, 327 (2014), sgRNA expression vectors targeting two target sequences (SEQ ID NOs: 26 and 27, located in the ALS coding sequence of the B genome and the ALS coding sequence of the D genome, respectively) were constructed.
[0199] 3. Gene bombardment transformation
[0200] The wheat (Triticum aestivum L.) variety used was winter wheat Conong 199. The PmCDA1-VQR-PBE plasmid and the sgRNA plasmid were mixed at a molar ratio of 1:1 using a gene gun-mediated transformation method and bombarded with wheat immature embryos. The specific process is referenced to Rasco-Gaunt (2001). Procedures allowing the transformation of a range of European elite wheat (Triticum aestivum L.) varieties via particle bombardment. J. Exp. Bot. 52, 865-874.
[0201] 4. Establishment of herbicide screening system
[0202] The existing wheat plants resistant to imazapic acid were used as positive controls, and wild-type wheat was used as negative controls. Different concentrations of imazapic acid were added to the wheat rooting medium, and the appropriate screening concentration was found, which was 1 / 15 of the field concentration of imazapic acid. At this concentration, the rooting of wild-type wheat was significantly inhibited, while the overexpressed positive wheat was able to root and grow normally.
[0203] 5. Genotype identification
[0204] The positive plants screened were sampled, and a small amount of plant genomic DNA was extracted using the Tiangen Express Plant Genome Extraction Kit (Tiangen DP321), and then the specific genotype was determined after Sanger sequencing. The results are shown in Table 1 below.
[0205] Table 1. Amino acid mutation types of TaALS-resistant mutant wheat (A genome-A99 corresponds to B genome-A98 and D genome-A96)
[0206]
[0207] Example 2: Generation and identification of wheat PPO-resistant mutants
[0208] 1. Single-base editing tools used
[0209] The A3A-PBE system fused with hAPOBEC3A cytosine deaminase was used (5. Zong, Y., et al. (2018). "Efficient C-to-T base editing in plants using a fusion of nCas9 and humanAPOBEC3A." Nat. Biotechnol. 36(10): 950).
[0210] 2. Construction of multi-target sgRNA expression vector
[0211] Design and synthesize primers with homologous sequences to the target sites.
[0212] T1(R98-AD)-F GAAGCGTTATACTGTTAAGGAGTTTTAGAGCTAGAAATAGC T1(R98-AD)-BsF ATATTGGTCTCTCTTGAAGCGTTATACTGTTAAGGAGTT T2(W1)-R CATCATGCGGCGGGGGACCTGCGCTTCTTGGTGCCGCGCC T2(W1)-F GCAGGTCCCCCGCCGCATGATGTTTTAGAGCTAGAAATAGC T3(R98-B)-R CTTCTTAACAGTATAACGCTTCGCCACGGATCATCTGCACAAC T3(R98-B)-BsR TTATAGGTCTCTAAACTTCTTAACAGTATAACGCTTCGC
[0213] According to the method of 3. Xing, HL et al. A CRISPR / Cas9 toolkit for multiplex genome editing in plants. BMC Plant Biol. 14, 327 (2014), sgRNA expression vectors targeting three target sequences (SEQ ID NOs: 28-30, located in the A genome PPO coding sequence, the B genome PPO coding sequence and the D genome PPO coding sequence, respectively) were constructed.
[0214] 3. Gene bombardment transformation
[0215] The wheat (Triticum aestivum L.) variety used was winter wheat Conong 199. The A3A-PBE plasmid and the sgRNA plasmid were mixed at a molar ratio of 1:1 using a gene gun-mediated transformation method and bombarded with immature wheat embryos. The specific process is described in Rasco-Gaunt et al. (2001). Procedures allowing the transformation of a range of European elite wheat (Triticum aestivum L.) varieties via particle bombardment. J. Exp. Bot. 52, 865-874.
[0216] 4. Establishment of herbicide screening system
[0217] Wheat plants overexpressing PPO protein were used as positive controls, and wild-type wheat was used as negative controls. Different concentrations of lactofenazole were added to the wheat rooting medium, and the appropriate screening concentration was found, which was 1 / 6 of the field use concentration of lactofenazole. At this concentration, the rooting of wild-type wheat was significantly inhibited, while the overexpressed positive wheat was able to root and grow normally.
[0218] 5. Genotype identification
[0219] The positive plants screened were sampled, and a small amount of plant genomic DNA was extracted using the Tiangen Express Plant Genome Extraction Kit (Tiangen DP321), and then the specific genotype was determined after Sanger sequencing. The results are shown in Table 2 below.
[0220] Table 2. Amino acid mutation types of PPO-resistant mutant wheat (A genome-R127 corresponds to B genome-R129 and D genome-R133)
[0221]
[0222]
[0223] Example 3 Generation and identification of rice ACCase-resistant mutants
[0224] 3.1 Construction of A3A-PBE-NG vector
[0225] Using pH-A3A-PBE vector (Q.Shan et al., Targeted genome modification of cropplants using a CRISPR-Cas system. Nature Biotechnology 31, 686 (2013)) as the basic framework, nCas9 was partially replaced with nCas9-NG containing D10A / R1335V / L1111R / D1135V / G1218R / E1219F / A1322R / T1337R mutations (Y.Zong et al., Efficient C-to-T baseediting in plants using a fusion of nCas9 and human APOBEC3A. Nat Biotechnol, (2018)) by the Gibson assembly method to obtain the base editing vector A3A-PBE-NG that can recognize the NG PAM sequence. The nCas9-NG sequence was synthesized by GENEWIZ (GENEWIZ, Suzhou, China).
[0226] 3.2 Construction of base editing vector targeting rice OsACC gene
[0227] Four target sequences targeting the carboxyltransferase (CT) domain of rice OsACC were selected (see Table 3), and base editing vectors targeting different sites in Table 3 were constructed according to the sgRNA vector construction method in the article reported by Yuan Zong (same as above).
[0228] Table 3
[0229]
[0230] Note: The underline is the PAM sequence
[0231] 3.3 Agrobacterium transformation of rice
[0232] The A3A-PBE-NG vector containing the sgRNA coding sequence for the target site was transformed into the Agrobacterium AGL1 strain by electroporation. Agrobacterium-mediated transformation, tissue culture and regeneration of rice cultivar Zhonghua 11 were performed according to Shan et al. Hygromycin selection (50 μg / ml) was used throughout the tissue culture process.
[0233] 3.4 Screening and identification of resistant plants
[0234] According to the growth status of the regenerated plants, the T0 generation plants regenerated on the culture medium were placed in water for 5 to 30 days for seedling hardening, and then the stems and leaves of the plants were directly sprayed with high-efficiency fluazifop-butyl, and the spraying concentration of the agent ranged from 0.1 to 2 times the recommended concentration of the purchased commercial preparation. After four weeks of spraying, a total of 5 surviving mutants were obtained, namely the herbicide-resistant mutants ( Figure 3 ).
[0235] DNA of the surviving mutants was extracted, the OsACC region containing the target sequence was amplified by PCR, and the mutation type of the resistant mutant was determined by Sanger sequencing. Figure 4 The C to T mutation at position 8 of the OsACC-S1866 target sequence (NG PAM is defined as positions 21 and 22 of the sgRNA target site) caused an amino acid change of S1866F, although a C to T mutation also occurred at position 18 of the OsACC-S1866 target sequence, but no amino acid change occurred; a G to C mutation at position 10 of the OsACC-A1884 target sequence caused an amino acid change of A1884P; a C to T mutation at position 11 of the OsACC-P2181 target sequence caused an amino acid change of P2181L; and a C to T mutation at positions 6 and 7 of the OsACC-P1927 target sequence caused an amino acid change of P1927F.
[0236] Example 4 Generation and identification of rice HPPD-resistant mutants
[0237] 4.1 Construction of base editing vector for rice HPPD
[0238] According to the literature, A3A-PBE fused with hAPOBEC3A cytosine deaminase was constructed (Zong, Y., et al. (2018). "Efficient C-to-T base editing in plants using a fusion of nCas9 and human APOBEC3A." Nat. Biotechnol. 36 (10): 950), and A3A-NG-PBE obtained by replacing the wild-type SpCas9 with the SpCas9-NG variant (Nishimasu, H. et al. (2018). Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 361, 1259-1262). PCR during vector construction was performed using TransStart FastPfu DNA polymerase (TransGen Biotech).
[0239] The target sequence of gRNA for rice HPPD was designed according to the coding sequence of rice HPPD (SEQ ID NO: 51), as shown in Table 4 below.
[0240] Table 4. Rice HPPD target sequences, divided into: NG PAM target sequence (including NGG), that is, the target sequence is located on the coding strand; CNPAM target sequence (including CCN), that is, the target sequence is located on the antisense strand. (The underlined PAM sequence)
[0241]
[0242]
[0243] 4.2 Agrobacterium transformation of rice
[0244] The A3A-PBE or A3A-PBE-NG vector containing the gRNA coding sequence for the target site was transformed into the Agrobacterium AGL1 strain by electroporation. The Agrobacterium-mediated transformation, tissue culture and regeneration of rice cultivars Nipponbare and Zhonghua 11 were carried out according to the method of Hiei et al. (Hiei, Y., and Komari, T. (2008). Agrobacterium-mediated transformation of rice using immature embryos or calliinduced from mature seed. Nat. Protoc. 3, 824-834). Hygromycin selection was used in all tissue culture processes.
[0245] 4.3 Screening of herbicide-resistant plants
[0246] Rice tissue culture seedlings overexpressing HPPD protein were used as positive controls, and wild-type rice plants of the same period and variety were used as negative controls. Each group of rice seedlings was sprayed with different concentration gradients of herbicides: mesotrione or basil. About two weeks later, at a suitable screening concentration, the leaves of the wild-type rice tissue culture seedlings without resistance turned white and slowly withered, while the leaves of the overexpressing positive rice tissue culture seedlings were normal and grew normally. The herbicide concentration, i.e., 1 / 8 of the field concentration of mesotrione or basil, was used as a suitable screening concentration. The rice plants obtained in Example 2 were treated with the screening concentration to obtain herbicide-resistant plants.
[0247] 4.4 Genotype identification
[0248] The positive plants screened in Example 3 were sampled, and a small amount of plant genomic DNA was extracted using the Tiangen Express Plant Genome Extraction Kit (Tiangen DP321), and then the specific genotype was determined after Sanger sequencing. The results are shown in Table 5 below:
[0249] Table 5. Resistant rice and its amino acid mutation types
[0250] Resistant mutant number Amino acid mutation M1 L365F M2 T379I M3 E353K&E354K M4 R346C&A347V M5 D369N&D370N
[0251] Sequence Listing
[0252] >SEQ ID NO:1TaALS-A amino acid sequence
[0253] MAAATSPAVAFSGAAAAAAAMPKPARQPLPRHQPASRRALPARVVRCCAAPPAAATSAAPPATALR
[0254] PWGPSEPRKGADILVEALERCGIVDVFAYPGGASMEIHQALTRSPVITNHLFRHEQGEAFAASGYAR
[0255] ASGRVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNY
[0256] LVLDVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPIWDTPMSLPGYIARLPKPPSTESLEQ
[0257] VLRLVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDDPLSLRMLGMHGTVYA
[0258] NYAVDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNA
[0259] LLNGSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQM
[0260] WAAQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIEN
[0261] LPVKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0262] >SEQ ID NO:2 TaALS-B Amino acid sequence
[0263] MAAATSPAVAFSGAAAAAAAIPKPARQPLPRHQPASRRALPARIVRCCAASPAATSVAPPATALRPW
[0264] GPSEPRKGADILVEALERCGIVDVFAYPGGASMEIHQALTRSPVITNHLFRHEQGEAFAASGYARAS
[0265] GRVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLV
[0266] LDVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVL
[0267] RLVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANY
[0268] AVDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNALL
[0269] NGSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMW
[0270] AAQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENL
[0271] PVKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0272] >SEQ ID NO:3 TaALS-D Amino acid sequence
[0273] MAAATSPAVAFSGATAAAMPKPARHPLPRHQPVSRRALPARVVRCCAASPAATSAAPPATALRPWG
[0274] PSEPRKGADILVEALERCGIVDVFAYPGGASMEIHQALTRSPVITNHLFRHEQGEAFAASGYARASG
[0275] RVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLVL
[0276] DVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVLR
[0277] LVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANYA
[0278] VDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNDLLN
[0279] GSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMWA
[0280] AQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENLP
[0281] VKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0282] >SEQ ID NO:4TaALS-A-A99T
[0283] MAAATSPAVAFSGAAAAAAAMPKPARQPLPRHQPASRRALPARVVRCCAAPPAAAPPATALR
[0284] PWGPSEPRKGADILVEALERCGIVDVFAYPGGTSMEIHQALTRSPVITNHLFRHEQGEAFAASGYAR
[0285] ASGRVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNY
[0286] LVLDVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPIWDTPMSLPGYIARLPKPPSTESLEQ
[0287] VLRLVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLLRMLGMHGTVYA
[0288] NYAVDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNA
[0289] LLNGSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQM
[0290] WAAQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIEN
[0291] LPVKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0292] >SEQ ID NO:5TaALS-B-A98T
[0293] MAAATSPAVAFSGAAAAAAAIPKPARQPLPRHQPASRRALPARIVRCCAASPAATSVAPPATALRPW
[0294] GPSEPRKGADILVEALERCGIVDVFAYPGGTSMEIHQALTRSPVITNHLFRHEQGEAFAASGYARAS
[0295] GRVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLV
[0296] LDVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVL
[0297] RLVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANY
[0298] AVDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNALL
[0299] NGSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMW
[0300] AAQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENL
[0301] PVKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0302] >SEQ ID NO:6TaALS-B-A98T / G97N
[0303] MAAATSPAVAFSGAAAAAAAIPKPARQPLPRHQPASRRALPARIVRCCAASPAATSVAPPATALRPW
[0304] GPSEPRKGADILVEALERCGIVDVFAYPGNTSMEIHQALTRSPVITNHLFRHEQGEAFAASGYARAS
[0305] GRVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLV
[0306] LDVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVL
[0307] RLVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANY
[0308] AVDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNALL
[0309] NGSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMW
[0310] AAQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENL
[0311] PVKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0312] >SEQ ID NO:7TaALS-B-E101K / M100I / A98T / G97N
[0313] MAAATSPAVAFSGAAAAAAAIPKPARQPLPRHQPASRRALPARIVRCCAASPAATSVAPPATALRPW
[0314] GPSEPRKGADILVEALERCGIVDVFAYPGNTSIKIHQALTRSPVITNHLFRHEQGEAFAASGYARASG
[0315] RVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLVL
[0316] DVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVLR
[0317] LVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANYA
[0318] VDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNALLN
[0319] GSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMWA
[0320] AQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENLP
[0321] VKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0322] >SEQ ID NO:8TaALS-D-A96T
[0323] MAAATSPAVAFSGATAAAMPKPARHPLPRHQPVSRRALPARVVRCCAASPAATSAAPPATALRPWG
[0324] PSEPRKGADILVEALERCGIVDVFAYPGGTSMEIHQALTRSPVITNHLFRHEQGEAFAASGYARASG
[0325] RVGVCVATSGPGATNLVSALADALLDSIPMVAITGQVPRRMIGTDAFQETPIVEVTRSITKHNYLVL
[0326] DVEDIPRVIQEAFFLASSGRPGPVLVDIPKDIQQQMAVPVWDTPMSLPGYIARLPKPPSTESLEQVLR
[0327] LVGESRRPILYVGGGCAASGEELRRFVELTGIPVTTTLMGLGNFPSDDPLSLRMLGMHGTVYANYA
[0328] VDKADLLLAFGVRFDDRVTGKIEAFASRSKIVHIDIDPAEIGKNKQPHVSICADVKLALQGLNDLLN
[0329] GSKAQQGLDFGPWHKELDQQKREFPLGFKTFGEAIPPQYAIQVLDELTKGEAIIATGVGQHQMWA
[0330] AQYYTYKRPRQWLSSSGLGAMGFGLPAAAGAAVANPGVTVVDIDGDGSFLMNIQELALIRIENLP
[0331] VKVMILNNQHLGMVVQWEDRFYKANRAHTYLGNPENESEIYPDFVTIAKGFNVPAVRVTKKSEVTAAIKKMLETPGPYLLDIIVPHQEHVLPMIPSGGAFKDMIMEGDGRTSY*
[0332] >SEQ ID NO:9TaPPO-A amino acid sequence
[0333] MLTSATAPSSSSCSHAPTRFASARGRRLRPVLAMAASDDPRARSVAVIGAGVSGLVAAYRLRKSGVR
[0334] VTVFEAEDRAGGKIRTNSDDGGFLWDEGANTMTESALEASRLIDDLGLEDRLQYPNSQHKRYTVKD
[0335] GAPALIPSDPIALMKSTVLSTKSKFKFFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFFERHFGKEVVD
[0336] YLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIVGAILSKLTAKGDSAKKGGTSSGKGRSKR
[0337] ASFSFHGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASSKELAKN
[0338] QSFDAVIMTAPLSNVQRMKFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGFGVLIPFK
[0339] EQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTPILKRFVTSDLTKLLGVKG
[0340] QPTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0341] >SEQ ID NO:10TaPPO-B amino acid sequence
[0342] MLTSATAPPSSSSCSSHAPTRFASARGRRLRPVLAMAASDDPRARSVAVVGAGVSGLVAAYRLRKS
[0343] GVRVTVFEAEDRAGGKIRTNSDGGFLWDEGANTMTESALEASRLIDDLGLEDRLQYPNSQHKRYT
[0344] VKNGAPALIPSDPIALMKSTVLSTKSKFKLFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERHFGKE
[0345] VVDYLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIVGAILSKLTAKGDSAKKGGASSGKGR
[0346] SKRASFSFHGGMQTLVDALHKEVGDNNVKLGTQVLSLACKCDELSASDGWSIFVDSKDATSKGL
[0347] AKNQSFDAVIMTAPLSNVQRMRFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGFGVLI
[0348] PFKEQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAAAPTATLKQFVTSDLTKLLG
[0349] VEGQPTFVKHIHWRDAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQAS*
[0350] >SEQ ID NO:11 TaPPO-D amino acid sequence
[0351] MLTSATAPSSSSSCAPTRFASSCRPRRSASARGRRPVLAMAASDDPRARSVAVVGAGVSGLVAAYR
[0352] LRKSGVRVTVFEAEDRAGGKIRTNSDGGFLWDEGANTMTESALEASRLIDDLGLEDRLQYPNSQH
[0353] KRYTVKDGAPALIPSDPIALMKSTLLSTSKSKFKLFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERH
[0354] FGREVVDYLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIWGAILSKLTAKGDSSKGGASS
[0355] GKGRSKRASSFHGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASS
[0356] KELAKNQSFDAVIMTAPLSNVQRMRFTKGGAPVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGF
[0357] GVLIPFKEQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTAILKQVTSDLTK
[0358] LLGVVGQPTTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0359] >SEQ ID NO:12TaPPO-A-R127C
[0360] MLTSATAPSSSCSSHAPTRFASARGRRLPVLAMAASDDPRARSVAVIGAGVSGLVAAYRLRKSGVR
[0361] VTVFEAEDRAGGKIRTNSDGGFLWDEGANTMTESALEASRLIDDLGLEDRLQYPNSQHKCYTVKD
[0362] GAPALISPDPIALMKSTVLSTKSKFKFFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERHFGKEVVD
[0363] YLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIWGAILSKLTAKGDSAKKKGGTSSKGRSKR
[0364] ASFSHFGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASSKELAKN
[0365] QSFDAVIMTAPLSNVQRMKFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGFGVLIPFK
[0366] EQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTPILKRWFTSDLTKLLGVKG
[0367] QPTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0368] >SEQ ID NO:13TaPPO-A-R127G
[0369] MLTSATAPSSSCSSHAPTRFASARGRRLPVLAMAASDDPRARSVAVIGAGVSGLVAAYRLRKSGVR
[0370] VTVFEAEDRAGGKIRTNSDGGFLWDEGANTMTESALEASRLIDDLGLEDRLQYPNSQHKGYTVKD
[0371] GAPALISPDPIALMKSTVLSTKSKFKFFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERHFGKEVVD
[0372] YLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIWGAILSKLTAKGDSAKKKGGTSSKGRSKR
[0373] ASFSHFGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASSKELAKN
[0374] QSFDAVIMTAPLSNVQRMKFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGFGVLIPFK
[0375] EQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTPILKRFVTSDLTKLLGVKG
[0376] QPTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0377] >SEQ ID NO:14TaPPO-B-R129C
[0378] MLTSATAPPSSSSCSSHAPTRFASARGRRLRPVLAMAASDDPRARSVAVVGAGVSGLVAAYLRRKS
[0379] GVRVTVFEAEDRAGGKIRTNSDGGFLDEGANTMTESALEASRLIDDLGLEDRLQYPNSQHKCYT
[0380] VKNGAPALIPSDPIALMKSTVLSTKSKFKLFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERHFGKE
[0381] VVDYLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIVGAILSKLTAKGDSAKKGGASSGKGR
[0382] SKRASFSFHGGMQTLVDALHKEVGDNNVKLGTQVLSLACKCDELSASDGWGSIFVDSKDATSKGL
[0383] AKNQSFDAVIMTAPLSNVQRMRFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGFGVLI
[0384] PFKEQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTIGGSHNRDLAAAPTATLKQVTSDLTKLLG
[0385] VEGQPTFVKHIHWRDAFPLYGHDYDSALEAIGKMESDLPGFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQAS*
[0386] >SEQ ID NO:15TaPPO-D-R133C
[0387] MLTSATAPSSSSSCAPTRFASSCRPRRSASARGRRPVLAMAASDDPRARSVAVVGAGVSGLVAAYR
[0388] LRKSGVRVTVFEAEDRAGGKIRTNSDGGFLDEGANTMTESALEASRLIDDLGLEDRLQYPNSQH
[0389] KCYTVKDGAPALIPSDPIALMKSTLLSTKSKFKLFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERH
[0390] FGREVVDYLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIVGAILSKLTAKGDSSKGGASS
[0391] GKGRSKRASFSFHGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASS
[0392] KELAKNQSFDAVIMTAPLSNVQRMRFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGF
[0393] GVLIPFKEQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTAILKQVTSDLTK
[0394] LLGVVGQPTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0395] >SEQ ID NO:16TaPPO-D-R133C / T135I
[0396] MLTSATAPSSSSSCAPTRFASSCRPRRSASARGRRPVLAMAASDDPRARSVAVVGAGVSGLVAAYR
[0397] LRKSGVRVTVFEAEDRAGGKIRTNSDGGFLDEGANTMTESALEASRLIDDLGLEDRLQYPNSQH
[0398] KCYIVKDGAPALIPSDPIALMKSTLLSTKSKFKLFLEPFLYEKSSTRNSKKVSDEHLRESVGSFFERH
[0399] FGREVVDYLIDPFVAGTSAGDPESLSIRHAFPGLWNLEKKYGSLIVGAILSKLTAKGDSSKGGASS
[0400] GKGRSKRASFSFHGGMQTLVDALHKEVGDSNVKLGTQVLSLACNCDELSASDGWSIFVDSKDASS
[0401] KELAKNQSFDAVIMTAPLSNVQRMRFTKGGAPFVLDFLPKVDYLPLSLMVTAFKKEDVKRPLEGF
[0402] GVLIPFKEQQKHGLKTLGTLFSSMMFPDRAPNDQYLFTTFIGGSHNRDLAGAPTAILKQVTSDLTK
[0403] LLGVVGQPTFVKHIHWRNAFPLYGHDYDSALEAIGKMESDLPGFFYAGNNKDGLAVGNVIASGSNTADLVISYLESGIKQVS*
[0404] >SEQ ID NO:17 wild type spCas9 amino acid sequence
[0405] MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRT
[0406] ARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
[0407] IYHLRKKLVDSTDKADLRIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI
[0408] NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSK
[0409] DTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLL
[0410] KALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK
[0411] QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKS
[0412] EETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGM
[0413] RKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII
[0414] KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLI
[0415] NGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIK
[0416] KGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHP
[0417] VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG
[0418] KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH
[0419] VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGT
[0420] ALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPL
[0421] IETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDP
[0422] KKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI
[0423] IKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE
[0424] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFD
[0425] TTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0426] >SEQ ID NO:18 nCas9(D10A) Amino Acid Sequence
[0427] MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRT
[0428] ARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
[0429] IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI
[0430] NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSK
[0431] DTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLL
[0432] KALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK
[0433] QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKS
[0434] EETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGM
[0435] RKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII
[0436] KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLI
[0437] NGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIK
[0438] KGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHP
[0439] VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG
[0440] KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH
[0441] VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGT
[0442] ALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPL
[0443] IETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDP
[0444] KKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI
[0445] IKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVE
[0446] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFD
[0447] TTIDRKRYTSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0448] >SEQ ID NO:19 nCas9-NG(D10A) Amino Acid Sequence
[0449] MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRT
[0450] ARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
[0451] IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI
[0452] NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSK
[0453] DTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLL
[0454] KALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK
[0455] QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKS
[0456] EETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGM
[0457] RKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII
[0458] KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLI
[0459] NGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIK
[0460] KGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHP
[0461] VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG
[0462] KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH
[0463] VAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGT
[0464] ALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPL
[0465] IETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDKLIARKKDWDP
[0466] KKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI
[0467] IKLPKYSLFELENGRKRMLASARFLQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQ
[0468] HKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPRAFKYFDT
[0469] TIDRKVYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0470] >SEQ ID NO:20 Amino acid sequence of nCas9-VQR(D10A)
[0471] MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRT
[0472] ARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT
[0473] IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI
[0474] NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSK
[0475] DTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLL
[0476] KALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK
[0477] QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKS
[0478] EETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGM
[0479] RKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII
[0480] KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLI
[0481] NGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIK
[0482] KGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHP
[0483] VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRG
[0484] KSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKH
[0485] VAQILDSRMNTKYDENDKLIREVQVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGT
[0486] ALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFKTEITLANGEIRKRPL
[0487] IETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDP
[0488] KKYGGFVSPTVAYSVVVAKVEKGKSKKKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLI
[0489] IKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHEKLKGSPEDNEQKQLFVE
[0490] QHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFD
[0491] TTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGD
[0492] >SEQ ID NO:21 is APOBEC3A
[0493] MEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLC
[0494] GFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYD
[0495] YDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQ
[0496] NQGN
[0497] >SEQ ID NO:22PmCDA1 amino acid sequence
[0498] MTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELKRRGERRACFWGYAVNKPQSGTERGI
[0499] HAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILEWYNQELRGNGHTLKIWACKLYYEKN
[0500] ARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQLNENRWLEKTLKRAEKRRSELSIMIQ
[0501] VKILHTTKSPAVSGSETPGTSESATPESLKMAPKKKRKVGIHGVPAA
[0502] >SEQ ID NO:23 DNA-dependent adenine deaminase ecTadA7.10 amino acid sequence
[0503] MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALR
[0504] QGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNH
[0505] RVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD
[0506] >SEQ ID NO:24 PmCDA1-VQR-PBE amino acid sequence
[0507] MLTLLFGVTSAKLVDGSMPKKKRKVMTDAEYVRIHEKLDIYTFKKQFFNNKKSVSHRCYVLFELK
[0508] RRGERRACFWGYAVNKPQSGTERGIHAEIFSIRKVEEYLRDNPGQFTINWYSSWSPCADCAEKILE
[0509] WYNQELRGNGHTLKIWACKLYEKNARNQIGLWNLRDNGVGLNVMVSEHYQCCRKIFIQSSHNQ
[0510] LNENRWLEKTLKRAEKRRSELSIMIQVKILHTTKSPAVSGSETPGTSESATPESLKMAPKKKRKVGI
[0511] HGVPAADKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEAT
[0512] RLKRTARARRYTRRKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYH
[0513] EKYPTIYHLRKKLVDSTDKADLRLIYLALAMHIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLF
[0514] EENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAK
[0515] LQLSKDTYDDLDNLLAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHH
[0516] QDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNRE
[0517] DLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAW
[0518] MTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKY
[0519] VTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYH
[0520] DLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRIEMIEERLKTYAHLFDDKVMKQLKRRRYTGWGR
[0521] LSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLA
[0522] GSPAIKKGILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIGELGSQ
[0523] ILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRS
[0524] DKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLTKAEGGGLSELDKAGFIKRQLVET
[0525] RQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLN
[0526] AVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFKTEITLANGEI
[0527] RKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARK
[0528] KDWDPKKYGGFVSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKE
[0529] VKKDLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQK
[0530] QLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAA
[0531] FKYFDTTIDRKQYRSTKEVLDATLIHQSITGLYETRIDLSQLGGDKRPAATKKAGQAKKKKTRDSG
[0532] GSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKP
[0533] WALVIQDSNGENKIKMLSGGSPKKKRKV
[0534] >SEQ ID NO:25A3A-PBE amino acid sequence
[0535] LTLLFGVTSAKLVDGSMEASPASGPRHLMDPHIFTSNFNNGIGRHKTYLCYEVERLDNGTSVKMD
[0536] QHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFL
[0537] QENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPWDG
[0538] LDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESLKDKKYSIGLAIGTNSVGWAVITDEYKVPS
[0539] KKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDD
[0540] SFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADLRLIYLALAHMI
[0541] KFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLP
[0542] GEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKN
[0543] LSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYI
[0544] DGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFY
[0545] PFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTN
[0546] FDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVK
[0547] QLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDRE
[0548] MIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQ
[0549] LIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVMGRHKPENIVIE
[0550] MARENQTTQKGQKNSRERMKRIEGIGELGSQILKEHPVENTQLQNEKLYLYYLQNGRDMYVDQ
[0551] ELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKL
[0552] ITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITL
[0553] KSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIA
[0554] KSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMP
[0555] QVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSK
[0556] KLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELENGRKRMLASAGELQK
[0557] GNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDK
[0558] VLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQSITGLYET
[0559] RIDLSQLGGDKRPAATKKAGQAKKKKTRDSGGSTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGN
[0560] KPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLSGGSPKKKRKV
[0561] >SEQ ID NO:26B Genomic ALS target sequence
[0562] CCTACCCTGGCGGCGCGTCC
[0563] >SEQ ID NO:27D Genomic ALS target sequence
[0564] CCTACCCCGGCGGCGCCTCC
[0565] >SEQ ID NO:28A Genomic PPO target sequence
[0566] AAGCGTTATACTGTTAAGGA
[0567] >SEQ ID NO:29B Genomic PPO target sequence
[0568] AAGCGTTATACTGTTAAGAA
[0569] >SEQ ID NO:30D Genomic PPO target sequence
[0570] AAGCGTTATACTGTTAAGGA
[0571] >SEQ ID NO:31 Rice ACCase full length amino acid sequence
[0572] MPMRPWEFIILGRTAPISPPPLGISAFSRPLRLRLRLRLAAVVDAARIQTPPRVAFSAFFFFFFFFSEGL
[0573] SREGTAARLPALIYRVPFIPCLLQLQIRAPHADPRPAGFSCAHHFLALAQGLSSSLLSGTISHIWGFIFS
[0574] LYGTTHLRNRAILLFGLAGIIDLPNDAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVS
[0575] KVVEFCTALGGKTPIHSVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHI
[0576] RIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAVWPGWGHASENPELPDALTAKGIVFLGPPAS
[0577] SMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDSIPDEMYRKACVTTTEEAVASCQVVG
[0578] YPAMIKASWGGGGKGIRKVHNDDEVRTLFKQVQGEVPGSPIFIMRLAAQSRHLEVQLLCDQYGNV
[0579] AALHSRDCSVQRRHQKIIEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
[0580] FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALAT
[0581] PFNFDEVDSKWPKGHCVAVRITSEDPDDGFKPTGKVKEISFKSKPNVWAYFSVKSGGGIHEFADS
[0582] QFGHVFAYGTTRSAAITTMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRV
[0583] QAERPPWYSVVGGALYKTTVTANTATVSDYVGYLTKGQIPPKHISLVYTTVALNIDGKKYTIDTVRS
[0584] GHGSYLRRMNGSTVDANVQILCDGGLLMQLDGNSHVIYAEEEASGTRLLIDGKTCMLQNDHDPS
[0585] KLLAETPCKLLRFLVADGAHVDADVPYAEVEVMKMCMPLLSPASGVIHVVMSEGQAMQAGDLIA
[0586] RLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDIDKVVPELVYCL
[0587] DTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEEYKVKFDSGIINDFPANMLRVIIEENLACGSEK
[0588] EKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKDLQK
[0589] VVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSEL
[0590] RARIARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLPVEDALISLFDCSDTTVQQRVIETYI
[0591] ARLYQPHLVKDSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRF
[0592] ALKETSHYTSSEGNMMHIALLGADNKMHIIQESGDDADRIAKLPLILKDNVTDLHASGVKTISFIV
[0593] QRDEARMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIY
[0594] TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAEEPLSFTSTSILRSLMTAIEELELHAI
[0595] RTGHSHMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLLKEMAMKIHELVGARMHHLSVCQ
[0596] WEVKLKLDCDGPASGTWRIVTTNVTSHTCTVDIYREMEDKESRKLVYHPATPAAGPLHGVALNNP
[0597] YQPLSVIDLKRCSARNNRTTYCYDFPL AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKH
[0598] GSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNL
[0599] ACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQL
[0600] DSGEIRWVIDSVVGKEDGLGVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQR
[0601] LDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGG
[0602] PLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRA
[0603] KLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFIL
[0604] ANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYA
[0605] ERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQL
[0606] MPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRISEDVLAKEIRAVAGEQFSH
[0607] QPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGL SML LDKMDPSRRAQLVEEIRKVLG*
[0608] >SEQ ID NO:32 Amino acid sequence of rice ACCase resistant mutant S1866F
[0609] MPMRPWEFIILGRTAPISPPPLGISAFSRPLRLRLRLRLAAVVDAARIQTPPRVAFSAFFFFFFFFSEGL
[0610] SREGTAARLPALIYRVPFIPCLLQLQIRAPHADPRPAGFSCAHHFLALAQGLSSSLLSGTISHIWGFIFS
[0611] LYGTTHLRNRAILLFGLAGIIDLPNDAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVS
[0612] KVVEFCTALGGKTPIHSVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHI
[0613] RIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAVWPGWGHASENPELPDALTAKGIVFLGPPAS
[0614] SMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDSIPDEMYRKACVTTTEEAVASCQVVG
[0615] YPAMIKASWGGGGKGIRKVHNDDEVRTLFKQVQGEVPGSPIFIMRLAAQSRHLEVQLLCDQYGNV
[0616] AALHSRDCSVQRRHQKIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
[0617] FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALAT
[0618] PFNFDEVDSKWPKGHCVAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADS
[0619] QFGHVFAYGTTRSAAITTMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRV
[0620] QAERPPWYISVVGGALYKTVTANTATVSDYVGYLTKGQIPPKHISLVYTTVALNIDGKKYTIDTVRS
[0621] GHGSYRLRMNGSTVDANVQILCDGGLLMQLDGNSHVIYAEEEASGTRLLIDGKTCMLQNDHDPS
[0622] KLLAETPCKLLRFLVADGAHVDADVPYAEVEVMKMCMPLLSPASGVIHVVMSEGQAMQAGDLIA
[0623] RLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDIDKVVPELVYCL
[0624] DTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPANMLRVIIEENLACGSEK
[0625] EKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKDLQK
[0626] VVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSEL
[0627] RARIARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLPVEDALISLFDCSDTTVQQRVIETYI
[0628] ARLYQPHLVKDSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRF
[0629] ALKETSHYTSSEGNMMHIALLGADNKMHIIQESGDDADRIAKLPLILKDNVTDLHASGVKTISFIV
[0630] QRDEARMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIY
[0631] TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAEEPLSFTSTSILRSLMTAIEELELHAI
[0632] RTGHSHMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLLKEMAMKIHELVGARMHHLSVCQ
[0633] WEVKLKLDCDGPASGTWRIVTTNVTSHTCTVDIYREMEDKESRKLVYHPATPAAGPLHGVALNNP
[0634] YQPLSVIDLKRCSARNNRTTYCYDFPL AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKH
[0635] GSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNL
[0636] ACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQL
[0637] DSGEIRWVIDFVVGKEDGLGVENIHGSAAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQR
[0638] LDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGG
[0639] PLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRA
[0640] KLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFIL
[0641] ANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYA
[0642] ERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQL
[0643] MPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRISEDVLAKEIRAVAGEQFSH
[0644] QPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGL SML LDKMDPSRRAQLVEEIRKVLG*
[0645] >SEQ ID NO:33 Amino acid sequence of rice ACCase resistant mutant A1884P
[0646] MPMRPWEFIILGRTAPISPPPLGISAFSRPLRLRLRLRLAAVVDAARIQTPPRVAFSAFFFFFFFFSEGL
[0647] SREGTAARLPALIYRVPFIPCLLQLQIRAPHADPRPAGFSCAHHFLALAQGLSSSLLSGTISHIWGFIFS
[0648] LYGTTHLRNRAILLFGLAGIIDLPNDAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVS
[0649] KVVEFCTALGGKTPIHSVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHI
[0650] RIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAVWPGWGHASENPELPDALTAKGIVFLGPPAS
[0651] SMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDSIPDEMYRKACVTTTEEAVASCQVVG
[0652] YPAMIKASWGGGGKGIRKVHNDDEVRTLFKQVQGEVPGSPIFIMRLAAQSRHLEVQLLCDQYGNV
[0653] AALHSRDCSVQRRHQKIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
[0654] FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALAT
[0655] PFNFDEVDSKWPKGHCVAVRITSEDPDDGFKPTGKVKEISFKSKPNVWAYFSVKSGGGIHEFADS
[0656] QFGHVFAYGTTRSAAITTMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRV
[0657] QAERPPWYSVVGGALYKTTVTANTATVSDYVGYLTKGQIPPKHISLVYTTVALNIDGKKYTIDTVRS
[0658] GHGSYLRRMNGSTVDANVQILCDGGLLMQLDGNSHVIYAEEEASGTRLLIDGKTCMLQNDHDPS
[0659] KLLAETPCKLLRFLVADGAHVDADVPYAEVEVMKMCMPLLSPASGVIHVVMSEGQAMQAGDLIA
[0660] RLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDIDKVVPELVYCL
[0661] DTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEEYKVKFDSGIINDFPANMLRVIIEENLACGSEK
[0662] EKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKDLQK
[0663] VVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSEL
[0664] RARIARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLVPEDALISLFDCSDTTVQQRVIETYI
[0665] ARLYQPHLVKDSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRF
[0666] ALKETSHYTSSEGNMMHIALLGADNKMHIIQESGDDADRIAKLPLILKDNVTDLHASGVKTISFIV
[0667] QRDEARMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIY
[0668] TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAEEPLSFTSTSILRSLMTAIEELELHAI
[0669] RTGHSHMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLLKEMAMKIHELVGARMHHLSVCQ
[0670] WEVKLKLDCDGPASGTWRIVTTNVTSHTCTVDIYREMEDKESRKLVYHPATPAAGPLHGVALNNP
[0671] YQPLSVIDLKRCSARNNRTTYCYDFPL AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKH
[0672] GSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNL
[0673] ACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQL
[0674] DSGEIRWVIDSVVGKEDGLGVENIHGSAPIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQR
[0675] LDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGG
[0676] PLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRA
[0677] KLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFIL
[0678] ANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYA
[0679] ERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQL
[0680] MPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRISEDVLAKEIRAVAGEQFSH
[0681] QPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGL SML LDKMDPSRRAQLVEEIRKVLG*
[0682] >SEQ ID NO:34 Amino acid sequence of rice ACCase resistant mutant P1927F
[0683] MPMRPWEFIILGRTAPISPPPLGISAFSRPLRLRLRLRLAAVVDAARIQTPPRVAFSAFFFFFFFFSEGL
[0684] SREGTAARLPALIYRVPFIPCLLQLQIRAPHADPRPAGFSCAHHFLALAQGLSSSLLSGTISHIWGFIFS
[0685] LYGTTHLRNRAILLFGLAGIIDLPNDAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVS
[0686] KVVEFCTALGGKTPIHSVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHI
[0687] RIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAVWPGWGHASENPELPDALTAKGIVFLGPPAS
[0688] SMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDSIPDEMYRKACVTTTEEAVASCQVVG
[0689] YPAMIKASWGGGGKGIRKVHNDDEVRTLFKQVQGEVPGSPIFIMRLAAQSRHLEVQLLCDQYGNV
[0690] AALHSRDCSVQRRHQKIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
[0691] FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALAT
[0692] PFNFDEVDSKWPKGHCVAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADS
[0693] QFGHVFAYGTTRSAAITTMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRV
[0694] QAERPPWYISVVGGALYKTVTANTATVSDYVGYLTKGQIPPKHISLVYTTVALNIDGKKYTIDTVRS
[0695] GHGSYRLRMNGSTVDANVQILCDGGLLMQLDGNSHVIYAEEEASGTRLLIDGKTCMLQNDHDPS
[0696] KLLAETPCKLLRFLVADGAHVDADVPYAEVEVMKMCMPLLSPASGVIHVVMSEGQAMQAGDLIA
[0697] RLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDIDKVVPELVYCL
[0698] DTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPANMLRVIIEENLACGSEK
[0699] EKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKDLQK
[0700] VVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSEL
[0701] RARIARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLPVEDALISLFDCSDTTVQQRVIETYI
[0702] ARLYQPHLVKDSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRF
[0703] ALKETSHYTSSEGNMMHIALLGADNKMHIIQESGDDADRIAKLPLILKDNVTDLHASGVKTISFIV
[0704] QRDEARMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIY
[0705] TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAEEPLSFTSTSILRSLMTAIEELELHAI
[0706] RTGHSHMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLLKEMAMKIHELVGARMHHLSVCQ
[0707] WEVKLKLDCDGPASGTWRIVTTNVTSHTCTVDIYREMEDKESRKLVYHPATPAAGPLHGVALNNP
[0708] YQPLSVIDLKRCSARNNRTTYCYDFPL AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKH
[0709] GSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNL
[0710] ACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQL
[0711] DSGEIRWVIDSVVGKEDGLVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQR
[0712] LDQFIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGG
[0713] PLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRA
[0714] KLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFIL
[0715] ANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYA
[0716] ERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQL
[0717] MPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSH
[0718] QPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGL SML LDKMDPSRRAQLVEEIRKVLG*
[0719] >SEQ ID NO:35 Amino acid sequence of rice ACCase resistant mutant P2181L
[0720] MPMRPWEFIILGRTAPISPPPLGISAFSRPLRLRLRLRLAAVVDAARIQTPPRVAFSAFFFFFFFFSEGL
[0721] SREGTAARLPALIYRVPFIPCLLQLQIRAPHADPRPAGFSCAHHFLALAQGLSSSLLSGTISHIWGFIFS
[0722] LYGTTHLRNRAILLFGLAGIIDLPNDAASEVDISHGSEDPRGPTVPGSYQMNGIINETHNGRHASVS
[0723] KVVEFCTALGGKTPIHSVLVANNGMAAAKFMRSVRTWANDTFGSEKAIQLIAMATPEDLRINAEHI
[0724] RIADQFVEVPGGTNNNNYANVQLIVEIAERTGVSAVWPGWGHASENPELPDALTAKGIVFLGPPAS
[0725] SMHALGDKVGSALIAQAAGVPTLAWSGSHVEVPLECCLDSIPDEMYRKACVTTTEEAVASCQVVG
[0726] YPAMIKASWGGGGKGIRKVHNDDEVRTLFKQVQGEVPGSPIFIMRLAAQSRHLEVQLLCDQYGNV
[0727] AALHSRDCSVQRRHQKIIEEGPVTVAPRETVKELEQAARRLAKAVGYVGAATVEYLYSMETGEYY
[0728] FLELNPRLQVEHPVTEWIAEVNLPAAQVAVGMGIPLWQIPEIRRFYGMNHGGGYDLWRKTAALAT
[0729] PFNFDEVDSKWPKGHCVAVRITSEDPDDGFKPTGGKVKEISFKSKPNVWAYFSVKSGGGIHEFADS
[0730] QFGHVFAYGTTRSAAITTMALALKEVQIRGEIHSNVDYTVDLLNASDFRENKIHTGWLDTRIAMRV
[0731] QAERPPWYISVVGGALYKTVTANTATVSDYVGYLTKGQIPPKHISLVYTTVALNIDGKKYTIDTVRS
[0732] GHGSYRLRMNGSTVDANVQILCDGGLLMQLDGNSHVIYAEEEASGTRLLIDGKTCMLQNDHDPS
[0733] KLLAETPCKLLRFLVADGAHVDADVPYAEVEVMKMCMPLLSPASGVIHVVMSEGQAMQAGDLIA
[0734] RLDLDDPSAVKRAEPFEDTFPQMGLPIAASGQVHKLCAASLNACRMILAGYEHDIDKVVPELVYCL
[0735] DTPELPFLQWEELMSVLATRLPRNLKSELEGKYEEYKVKFDSGIINDFPANMLRVIIEENLACGSEK
[0736] EKATNERLVEPLMSLLKSYEGGRESHAHFVVKSLFEEYLYVEELFSDGIQSDVIERLRLQHSKDLQK
[0737] VVDIVLSHQSVRNKTKLILKLMESLVYPNPAAYRDQLIRFSSLNHKAYYKLALKASELLEQTKLSEL
[0738] RARIARSLSELEMFTEESKGLSMHKREIAIKESMEDLVTAPLPVEDALISLFDCSDTTVQQRVIETYI
[0739] ARLYQPHLVKDSIKMKWIESGVIALWEFPEGHFDARNGGAVLGDKRWGAMVIVKSLESLSMAIRF
[0740] ALKETSHYTSSEGNMMHIALLGADNKMHIIQESGDDADRIAKLPLILKDNVTDLHASGVKTISFIV
[0741] QRDEARMTMRRTFLWSDEKLSYEEEPILRHVEPPLSALLELDKLKVKGYNEMKYTPSRDRQWHIY
[0742] TLRNTENPKMLHRVFFRTLVRQPSVSNKFSSGQIGDMEVGSAEEPLSFTSTSILRSLMTAIEELELHAI
[0743] RTGHSHMYLHVLKEQKLLDLVPVSGNTVLDVGQDEATAYSLLKEMAMKIHELVGARMHHLSVCQ
[0744] WEVKLKLDCDGPASGTWRIVTTNVTSHTCTVDIYREMEDKESRKLVYHPATPAAGPLHGVALNNP
[0745] YQPLSVIDLKRCSARNNRTTYCYDFPL AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKH
[0746] GSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSGFGPREDAFFEAVTNL
[0747] ACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQL
[0748] DSGEIRWVIDSVVGKEDGLGVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQR
[0749] LDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGG
[0750] PLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRA
[0751] KLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFIL
[0752] ANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINLDRIECYA
[0753] ERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQL
[0754] MPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSH
[0755] QPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGL SML LDKMDPSRRAQLVEEIRKVLG*
[0756] >SEQ ID NO:36 Amino acid sequence of the CT domain of wild - type rice OsACC
[0757] AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKHGSWGTPLVQMDRPAGLNDIGMVAWT
[0758] LKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVK
[0759] SCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVENIH
[0760] GSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQRLDQPIILTGYSALNKLLGREVYSSH
[0761] MQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLPVTTPLDPPDRPVAYIPENSCDP
[0762] RAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMMQTIPAD
[0763] PGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGST
[0764] IVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEEL
[0765] QDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQLMPLYTQIAIRFAELHDTSLRMAA
[0766] KGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSHQPAIELIKKWYSASHAAEWDDD
[0767] DAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGLSML
[0768] >SEQ ID NO:37 Amino acid sequence of the CT domain of the rice OsACC resistance mutant S1866F AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKHGSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDFVVGKEDGLGVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQRLDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQLMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSHQPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGLSML
[0769] >SEQ ID NO:38 Amino acid sequence of the CT domain of rice OsACC resistance mutant A1884P AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKHGSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVENIHGSAPIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQRLDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQLMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSHQPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGLSML
[0770] >SEQ ID NO:39 Amino acid sequence of the CT domain of the rice OsACC resistance mutant P1927F AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKHGSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQRLDQFIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINPDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQLMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSHQPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGLSML
[0771] >SEQ ID NO:40 Amino acid sequence of the CT domain of the rice OsACC resistance mutant P2181L AFETAVRKSWSSSTSGASKGVENAQCYVKATELVFADKHGSWGTPLVQMDRPAGLNDIGMVAWTLKMSTPEFPSGREIIVVANDITFRAGSFGPREDAFFEAVTNLACEKKLPLIYLAANSGARIGIADEVKSCFRVGWSDDGSPERGFQYIYLSEEDYARIGTSVIAHKMQLDSGEIRWVIDSVVGKEDGLGVENIHGSAAIASAYSRAYKETFTLTFVTGRTVGIGAYLARLGIRCIQRLDQPIILTGYSALNKLLGREVYSSHMQLGGPKIMATNGVVHLTVSDDLEGVSNILRWLSYVPAYIGGPLPVTTPLDPPDRPVAYIPENSCDPRAAIRGVDDSQGKWLGGMFDKDSFVETFEGWAKTVVTGRAKLGGIPVGVIAVETQTMMQTIPADPGQLDSREQSVPRAGQVWFPDSATKTAQALLDFNREGLPLFILANWRGFSGGQRDLFEGILQAGSTIVENLRTYNQPAFVYIPMAAELRGGAWVVVDSKINLDRIECYAERTAKGNVLEPQGLIEIKFRSEELQDCMSRLDPTLIDLKAKLEVANKNGSADTKSLQENIEARTKQLMPLYTQIAIRFAELHDTSLRMAAKGVIKKVVDWEESRSFFYKRLRRRISEDVLAKEIRAVAGEQFSHQPAIELIKKWYSASHAAEWDDDDAFVAWMDNPENYKDYIQYLKAQRVSQSLSSLSDSSSDLQALPQGLSML
[0772] >SEQ ID NO:41 OsACC-S1866 target sequence
[0773] ATTGATTCTGTTGTGGGCAA
[0774] >SEQ ID NO:42 OsACC-A1884 target sequence
[0775] TGGAAGTGCTGCTATTGCCA
[0776] >SEQ ID NO:43 Target sequence of OsACC-P1927
[0777] ACCAGCCTATTATTCTTACA
[0778] >SEQ ID NO:44 Target sequence of OsACC-P2181
[0779] AAGATAAACCCAGACCGCAT
[0780] >SEQ ID NO:45 Wild type of OsHPPD
[0781] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0782] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0783] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0784] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0785] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLREMRARSAM
[0786] GGFEFLAPPPPNYYDGVRRRAGDVLSEEQINECQELGVLVDRDDQGVLLQIFTKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0787] >SEQ ID NO:46 OsHPPD-M1(L365F)
[0788] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0789] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0790] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0791] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0792] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLREMRARSAM
[0793] GGFEFLAPPPPNYYDGVRRRAGDVLSEEQINECQELGVFVDRDDQGVLLQIFTKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0794] >SEQ ID NO:47OsHPPD-M2(T379I)
[0795] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0796] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0797] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0798] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0799] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLREMRARSAM
[0800] GGFEFLAPPPPNYYDGVRRRAGDVLSEEQINECQELGVLVDRDDQGVLLQIFIKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0801] >SEQ ID NO:48OsHPPD-M3(E353K / E354K)
[0802] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0803] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0804] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0805] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0806] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLRREMRARSAM
[0807] GGFEFLAPPPPNYYDGVRRRAGDVLSKKQINECQELGVLVDRDDQGVLLQIFTKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0808] >SEQ ID NO:49OsHPPD-M4(R346C / A347V)
[0809] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0810] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0811] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0812] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0813] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLREMRARSAM
[0814] GGFEFLAPPPPNYYDGVRRCVGDVLSEEQINECQELGVLVDRDDQGVLLQIFTKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0815] >SEQ ID NO:50OsHPPD-M5(D369N / D370N)
[0816] MPPTPTPTATTGAVSAAAAAGENAGFRLVGHRRFVRANPRSDRFQALAFHHVELWCADAASAAG
[0817] RFAFALGAPLAARSDLSTGNSAHASLLLRSASVAFLFTAPYGGDHGVGADAATTASIPSFSPGAARR
[0818] FAADHGLAVHAVALRVADAADAFRASVAAGARPAFQPADLGGGFGLAEVELYGDVVLRFVSHPDG
[0819] ADAPFLPGFEGVSNPGAVDYGLRRFDHVVGNVPELAPVAAYISGFTGFHEFAEFTAEDVGTAESGL
[0820] NSVVLANNAETVLLPLNEPVHGTKRRSQIQTYLDHHGGPGVQHIALASDDVLGTLREMRARSAM
[0821] GGFEFLAPPPPNYYDGVRRRAGDVLSEEQINECQELGVLVDRNNQGVLLQIFTKPVGDRPTFFLEMIQRIGCMEKDESGQEYQKGGCGGFGKGNFSELFKSIEEYEKSLEAKQAPTVQGS*
[0822] >SEQ ID NO:51 Coding sequence of rice HPPD
[0823] ATGCCTCCCACTCCCACCCCCACCGCCACCACCGGCGCCGTCTCGGCCGCTGCGGCGGCGGGG
[0824] GAGAACGCGGGGTTCCGCCTCGTCGGGCACCGCCGCTTCGTCCGCGCCAACCCGCGGAGCGA
[0825] CCGGTTCCAGGCGCTCGCGTTCCACCACGTCGAGCTCTGGTGCGCCGACGCCGCGTCCGCCGC
[0826] GGGCCGGTTCGCCTTCGCCCTGGGCGCGCCGCTCGCCGCCAGGTCCGACCTCTCCACGGGGAA
[0827] CTCCGCGCACGCCTCCCTCCTCCTCCGCTCCGCCTCCGTCGCGTTCCTCTTCACCGCCCCCTAC
[0828] GGCGGCGACCACGGCGTCGGCGCGGACGCGGCCACCACCGCCTCCATCCCTTCCTTCTCCCCA
[0829] GGCGCCGCGCGGAGGTTCGCCGCGGACCACGGCCTCGCGGTGCACGCCGTGGCGCTGCGCGT
[0830] CGCCGACGCGGCCGACGCCTTCCGCGCCAGCGTCGCGGCCGGTGCGCGCCCGGCGTTCCAGCC
[0831] CGCCGACCTCGGCGGTGGCTTCGGCCTCGCGGAGGTGGAGCTCTACGGCGACGTCGTGCTCCG
[0832] CTTCGTCAGCCACCCGGACGGCGCCGACGCGCCCTTCCTCCCGGGTTTCGAGGGCGTCAGCAA
[0833] CCCGGGCGCCGTGGACTACGGCCTCCGCCGGTTCGACCACGTCGTCGGCAACGTGCCGGAGCT
[0834] CGCTCCGGTAGCCGCGTACATCTCCGGGTTCACCGGGTTCCACGAGTTCGCCGAGTTCACCGCC
[0835] GAGGACGTGGGCACCGCCGAGAGCGGCCTCAACTCGGTGGTGCTCGCCAACAACGCGGAGAC
[0836] CGTGCTGCTGCCGCTCAACGAGCCGGTGCACGGCACCAAGCGGCGGAGCCAGATACAGACGT
[0837] ACCTGGACCACCACGGCGGCCCGGGGGTGCAGCACATCGCGCTGGCCAGCGACGACGTGCTC
[0838] GGGACGCTGAGGGAGATGCGGGCGCGCTCCGCCATGGGCGGCTTCGAGTTCTTGGCGCCGCCG
[0839] CCGCCCAACTACTACGACGGCGTGCGGCGGCGCGCCGGGGACGTGCTCTCGGAGGAGCAGAT
[0840] CAACGAGTGCCAGGAGCTCGGGGTGCTCGTGGACAGGGATGACCAGGGGGTGTTGCTCCAGA
[0841] TCTTCACCAAGCCAGTAGGAGACAGGCCAACCTTTTTCTTGGAGATGATACAAAGGATTGGGT
[0842] GCATGGAGAAGGATGAGAGTGGGCAGGAGTACCAGAAGGGCGGCTGCGGCGGGTTTGGGAAG
[0843] GGCAACTTCTCGGAGCTGTTCAAGTCCATTGAGGAGTATGAGAAATCCCTTGAAGCCAAGCAA
[0844] GCCCCTACAGTTCAAGGATCCTAG
[0845] >SEQ ID NO:52 Target sequence 1
[0846] GTGCGGCGGCGCGCCGGGGA
[0847] >SEQ ID NO:53 Target sequence 2
[0848] GCGCGCCGGGGACGTGCTCT
[0849] >SEQ ID NO:54 Target sequence 3
[0850] GGACGTGCTCTCGGAGGAGC
[0851] >SEQ ID NO:55 Target sequence 4
[0852] CTCGGAGGAGCAGATCAACG
[0853] >SEQ ID NO:56 Target sequence 5
[0854] TGCCAGGAGCTCGGGGTGCT
[0855] >SEQ ID NO:57 Target sequence 6
[0856] AGCTCGGGGTGCTCGTGGAC
[0857] >SEQ ID NO:58 Target sequence 7
[0858] TGACCAGGGGGTGTTGCTCC
[0859] >SEQ ID NO:59 Target sequence 8
[0860] GTTGCTCCAGATCTTCACCA
[0861] >SEQ ID NO:60 Target sequence 9
[0862] TCACCAAGCCAGTAGGAGAC
[0863] >SEQ ID NO:61 Target sequence 10
[0864] GCCAACCTTTTTCTTGGAGA
[0865] >SEQ ID NO:62 Target sequence 11
[0866] GATACAAAGGATTGGGTGCA
[0867] >SEQ ID NO:63 Target sequence 12
[0868] AGTGGGCAGGAGTACCAGAA
[0869] >SEQ ID NO:64 Target sequence 13
[0870] GAGTACCAGAAGGGCGGCTG
[0871] >SEQ ID NO:65 Target sequence 14
[0872] CAACTTCTCGGAGCTGTTCA
[0873] >SEQ ID NO:66 Target sequence 15
[0874] CAAGTCCATTGAGGAGTATG
[0875] >SEQ ID NO:67 Target sequence 16
[0876] AAATCCCTTGAAGCCAAGCA
[0877] >SEQ ID NO:68 target sequence 17GAAGCCAAGCAAGCCCCTAC>SEQ ID NO:69 target sequence 18CTTGAAGCCAAGCAAGCCCC>SEQ ID NO:70 target sequence 19AGTCCATTGAGGAGTATGAG>SEQ ID NO:71 target sequence 20ACTTCTCGGAGCTGTTCAAG>SEQ ID NO:72 target sequence 21GCGGCGGGTTTGGGAAGGGC>SEQ ID NO:73 target sequence 22GGAGTACCAGAAGGGCGGCT>SEQ ID NO:74 target sequence 23GAAGGGCGGCTGCGGCGGGT>SEQ ID NO:75 target sequence 24TGGAGAAGGATGAGAGTGGG>SEQ ID NO:76 target sequence 25AAGGATTGGGTGCATGGAGA>SEQ ID NO:77 target sequence 26TGGAGATGATACAAAGGATT>SEQ ID NO:78 target sequence 27ACCTTTTTCTTGGAGATGAT>SEQ ID NO:79 target sequence 28GCTATTTCACTCAGGCCAAC>SEQ ID NO:80 target sequence 29TCACCAAGCCAGTAGGAGAC>SEQ ID NO:81 target sequence 30GGGATGACCAGGGGGTGTTG>SEQ ID NO:82 target sequence 31CGTGGACAGGGATGACCAGG>SEQ ID NO:83 target sequence 32CGGGGTGCTCGTGGACAGGG>SEQ ID NO:84 target sequence 33AGTGCCAGGAGCTCGGGGTG>SEQ ID NO:85 target sequence 34GATCAACGAGTGCCAGGAGC>SEQ ID NO:86 target sequence 35GGGACGTGCTCTCGGAGGAG
[0878] >SEQ ID NO:87 Target sequence 36
[0879] GCGGCGCGCCGGGGACGTGC
[0880] >SEQ ID NO:88 Target sequence 37
[0881] GCGTGCGGCGGCGCGCCGGG
[0882] >SEQ ID NO:89A3A-NG-PBE
[0883] MWIFLALPSYAIYLLGTVSFVDAHPVVWCYFCSPRMEASPASGPRHLMDPHIFTSNFNNGIGRHKT
[0884] YLCYEVERLDNGTSVKMDQHRGFLHNQAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFI
[0885] SWSPCFSWGCAGEVRAFLQENTHVRLRIFAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFKHC
[0886] WDTFVDHQGCPFQPWDGLDEHSQALSGRLRAILQNQGNSGSETPGTSESATPESRPDKKYSIGLAI
[0887] GTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKN
[0888] RICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDS
[0889] TDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAIL
[0890] SARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNL
[0891] LAQIGDQYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPE
[0892] KYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPH
[0893] QIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEE
[0894] VVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQK
[0895] KAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKIIKDKDFLDNEEN
[0896] EDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTI
[0897] LDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVD
[0898] ELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIGELGSQILKEHPVENTQLQNEKL
[0899] YLYYLQNGRDMYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVV
[0900] KKMKNYWRQLLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNT
[0901] KYDENDKLIREVKIVTLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESE
[0902] FVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEITLANGEIRKRPLIETNGETGEIVW
[0903] DKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESIRPKRNSDKLIARKDWDPKKYGGFVSPTV
[0904] AYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKYSLFELE
[0905] NGRKRMLASARFLQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLDEIIIEQI
[0906] SEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPRAFKYFDTTIDRKVYRSTK
[0907] EVLDATLIHQSITGLYETRIDLSQLGGDKRPAATKKAGQAKKKKTRDSGGSTNLSDIIEKETGKQLVI
[0908] QESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKMLS
[0909] GGSPKKKRKV
Claims
1. A PPO mutant, wherein relative to wild-type PPO, the PPO mutant comprises one or more amino acid substitutions selected from R127C, R127G, T129I, wherein the amino acid positions refer to SEQ ID NO:
9.
2. The PPO mutant according to claim 1, wherein relative to wild-type PPO, the PPO mutant comprises an R127C amino acid substitution, the amino acid position being referenced to SEQ ID NO:
9.
3. The PPO mutant of claim 1, wherein the PPO mutant, when expressed in a rice plant, can confer resistance to a herbicide on the rice plant.
4. The PPO mutant according to claim 1, wherein the herbicide is selected from diphenyl ethers, cyclic imines, phenylpyrazoles, bicyclic triazolone compounds, or any combination thereof. The PPO mutant according to claim 1 , wherein the herbicide is selected from the group consisting of aryloxyphenoxypropionate herbicides. 6 . The PPO mutant according to claim 1 , wherein the PPO mutant comprises the amino acid sequence shown in any one of SEQ ID NOs: 12-16.
7. A nucleic acid comprising a nucleotide sequence encoding the PPO mutant according to any one of claims 1 to 6.
8. An expression cassette comprising a nucleotide sequence encoding the PPO mutant according to any one of claims 1 to 6 operably linked to a regulatory sequence.
9. An expression construct comprising the expression cassette of claim 8.
10. A method for producing herbicide-resistant plants by transgenic means, said method comprising introducing into said plant the nucleic acid of claim 7, the expression cassette of claim 8 and / or the expression construct of claim 9.
11. The method according to claim 10, wherein the herbicide is an aryloxyphenoxypropionate herbicide.
12. The method of claim 10, wherein the plant is rice.
13. A method for producing a herbicide-resistant plant by base editing, the method comprising introducing a base editing system targeting an endogenous PPO coding region in the plant genome into the plant, thereby causing the endogenous PPO to contain one or more amino acid substitutions selected from R127C, R127G, T129I, the amino acid positions refer to SEQ ID NO: 9; The base editing system comprises a base editing fusion protein or an expression construct comprising a nucleotide sequence encoding a base editing fusion protein, and at least one guide RNA or an expression construct comprising a nucleotide sequence encoding at least one guide RNA, wherein the base editing fusion protein comprises a CRISPR effector protein and a deaminase domain, and the at least one guide RNA is capable of targeting the base editing fusion protein to an endogenous PPO coding sequence in a plant genome.
14. The method according to claim 13, wherein the herbicide is an aryloxyphenoxypropionate herbicide.
15. The method of claim 13, wherein the plant is rice.
16. The method of claim 13, wherein the base editing fusion protein is an amino acid sequence shown in SEQ ID NO: 24 or 25, and the at least one guide RNA is a nucleotide sequence selected from SEQ ID NO: 28-30 or a complementary sequence thereof.
